

BMJ Open

Effect of salt reduction on iodine status assessed by 24h urinary iodine excretion in children and their families in northern China: a cluster randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-011168
Article Type:	Research
Date Submitted by the Author:	15-Jan-2016
Complete List of Authors:	He, Feng; Queen Mary University of London, Wolfson Institute of Preventive Medicine Ma, Yuan; Peking University School of Public Health, Feng, Xiangxian; Changzhi Medical College Zhang, Wanqi; Tianjin Medical University Lin, Laixiang; Key Laboratory of Hormone and Development (Ministry of Health) Guo, Xiaohui; Tianjin Medical University Zhang, Jing; The George Institute for Global Health at Peking University Health Science Center, Niu, Wenyi; Peking University School of Public Health Wu, Yangfeng; The George Institute, MacGregor, Graham; Queen Mary University of London, Wolfson Institute of Preventive Medicine
Primary Subject Heading:	Public health
Secondary Subject Heading:	Nutrition and metabolism
Keywords:	Salt reduction, Iodine status, 24h urine collections, Cluster randomised trial

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Effect of salt reduction on iodine status assessed by 24h urinary iodine excretion in children and their families in northern China: a cluster randomised controlled trial

Feng J He,¹ Yuan Ma,^{1,2,3} Xiangxian Feng,⁴ Wanqi Zhang,^{5,6} Laixiang Lin,^{6,7} Xiaohui Guo,⁵ Jing Zhang,² Wenyi Niu,⁸ Yangfeng Wu,^{2,3,9} Graham A MacGregor¹

¹ Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, UK.

² The George Institute for Global Health at Peking University Health Science Center, Beijing, China.

³ Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing, China.

⁴ Changzhi Medical College, Shanxi, China.

⁵ School of Public Health, Tianjin Medical University, Tianjin, China.

⁶ Key Laboratory of Hormone and Development (Ministry of Health), China.

⁷ Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.

⁸ Department of Social Medicine and Health Education, Peking University School of Public Health, Beijing, China.

⁹ Peking University Clinical Research Institute, Beijing, China.

Running Title: Effect of salt reduction on iodine status

Correspondence to:

Dr. Feng J He

Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ.

Tel: +44 (0)20 7882 6266

Fax: +44 (0)20 7882 6270

E-mail: f.he@qmul.ac.uk

Professor Wanqi Zhang

School of Public Health, Tianjin Medical University, Tianjin, China. 300070

Tel: +86 (0)22 8333 6595

Fax: +86 (0)22 8333 6608

E-mail: wqzhang@tmu.edu.cn

Abstract

Objective To study the effect of salt reduction on iodine status and to determine whether iodine consumption was still adequate after salt intake was reduced in a population where universal salt iodisation is mandatory.

Design Cluster randomised controlled trial, with schools randomly assigned to either the intervention or control group.

Setting 28 primary schools in urban Changzhi, northern China.

Participants 279 children in grade 5 of primary school (mean age: 10.1); 553 adults (age: 43.8).

Intervention Children were educated about the harmful effects of salt and how to reduce salt intake using the schools' usual health education lessons. Children then delivered the message to their families. The duration was one school term (≈ 3.5 months).

Main outcome measure Difference between the intervention and control group in the change of iodine intake as measured by repeat 24h urinary iodine from baseline to the end of the trial.

Results At baseline, the mean salt intake was 7.0 ± 2.5 g/d in children and 11.7 ± 4.4 g/d in adults and the median iodine intake was 165.1 μ g/d (IQR: 122.6-216.7) and 280.7 μ g/d (IQR: 205.1-380.9) in children and adults respectively. At the end of the study, both salt and iodine decreased in the intervention compared with control group. The mean effect on salt for intervention vs control was -1.9 g/d (95% CI: -2.6 to -1.3) in children and -2.9 g/d (95% CI: -3.7 to -2.2) in adults. The mean effect on iodine was -19.3% (95% CI: -29.4% to -7.7%) in children and -11.4% (95% CI: -20.3% to -1.5%) in adults.

Conclusions With $\approx 25\%$ reduction in salt intake, there was a significant reduction in iodine consumption in northern China where salt is iodised. Despite this, iodine intake was

1
2
3 still adequate, and well above the estimated average requirement. Our findings indicate that
4
5 reducing salt to the WHO's target—30% reduction by 2025, will not compromise iodine
6
7 status.
8

9
10 **Trial registration** ClinicalTrials.gov NCT01821144.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- 24h urinary iodine excretion is the most reliable biochemical marker for assessing iodine status. However, almost all previous surveys on iodine have used spot urine due to the apparent logistic challenges and costs in collecting 24h urine. Our study is the first to have assessed iodine status by repeat 24h urine collections in a large number of primary school children and their adult family members in northern China where universal salt iodisation is mandatory.
- Our study, for the first time, has assessed the effect of a modest reduction in salt intake, as currently recommended, on iodine status using a well-controlled randomised trial. The findings provide strong support for the WHO's recommendations to reduce population salt intake to prevent cardiovascular disease, and to improve iodine intake by fortifying salt with iodine to prevent iodine deficiency.
- Despite all 24h urine collections followed stringent protocol with careful supervision, there might still be under collections in some participants. However, the consistent findings from various sensitivity analyses indicate that this is unlikely to alter the primary outcome.

Introduction

A reduction in salt intake is one of the most cost-effective public health policies to prevent hypertension and cardiovascular disease.¹⁻³ The WHO recommends a 30% reduction in salt intake by 2025 for all countries around the world with an eventual target of 5 g/d.⁴ At the same time, salt has been used as a vehicle for iodine fortification to prevent iodine deficiency in many countries. It is therefore important to monitor iodine status to ensure that iodine consumption is still adequate when salt intake is reduced.

More than 90% of iodine consumed is excreted in the urine within 24-48 hours.^{5,6} Therefore, 24h urinary iodine excretion is a good marker of recent dietary iodine intake and is the ideal biochemical indicator for assessing iodine status.⁷ We measured 24h urinary iodine excretion in individuals who took part in School-EduSalt (**School-based Education Programme to Reduce Salt**),^{8,9} a cluster randomised controlled trial in Changzhi, northern China where universal salt iodisation is mandatory. The primary aim of the School-EduSalt trial was to determine whether an education programme targeted at primary school children could lower salt intake in children and their families. The study collected two consecutive 24h urines at baseline and at the end of the trial using a standardised protocol with careful supervision. The results showed that the education led to a significant reduction in salt intake by approximately 25% in both children and adults compared with the controls. In this paper, we report a pre-specified sub-study, the aim of which was to assess iodine status by repeat 24h urinary iodine excretion and to study the effect of salt reduction on iodine status, and in particular to determine whether iodine consumption was still adequate after the participants had been on a reduced salt intake for a few months.

Methods

Study design and participants

1
2
3 A detailed description of the methods of the School-EduSalt study has been published
4 elsewhere^{8,9} and only methods relevant to the current study are reported in brief here.
5
6

7 The study was a cluster randomised controlled trial. We recruited 28 primary schools in
8 urban Changzhi. From each school, we selected one class in Grade 5 (age ≈10 years). From
9 each class we randomly selected 10 children for assessment and the inclusion criteria were
10 eating home-made meals for at least 3 days a week and children's home not too far from the
11 school (less than 3 km). From each child's family we also enrolled two adults who shared the
12 same meals with the child.
13
14
15
16
17
18
19

20 21 **Randomisation**

22 Schools (clusters) were randomly assigned (1:1) to either the intervention or the control
23 group with stratification by the location of schools (i.e. urban or suburban) and the size of the
24 class. The randomisation was carried out using computer generated random number system
25 by an independent statistician who was blinded to the identity of the schools. The
26 randomisation took place after written consents had been obtained and the baseline
27 assessments had completed. Therefore, the participants, the school teachers and the local
28 investigators who undertook participant recruitment and data collection, were unaware of the
29 allocation until the point prior to the commencement of the intervention.
30
31
32
33
34
35
36
37
38
39
40
41

42 43 **Intervention**

44 Children in the intervention group were educated about the harmful effects of salt on health
45 and how to reduce salt intake using the schools' usual health education lessons, i.e. one 40
46 min lesson every two weeks.^{8,9} The salt reduction education was delivered to the whole class
47 in spite of only 10 children being selected for assessment. Children were asked to deliver the
48 salt reduction message to the families, particularly children needed to persuade the persons
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 who did the cooking to reduce the amount of salt used during food preparation at home. The
4
5 duration of the intervention was one school term (≈ 3.5 months).
6

7
8 Children in the control group carried on with their usual health education lessons as in the
9
10 curriculum and these lessons did not contain information on salt.
11

12 **Outcome measures**

13
14
15 The primary outcome of the School-EduSalt trial was the difference between the intervention
16
17 and the control group in the change of salt intake as measured by 24h urinary sodium
18
19 excretion from baseline to the end of the trial. The primary outcome of the present sub-study
20
21 was the difference between the intervention and the control group in the change of iodine
22
23 intake as measured by 24h urinary iodine excretion from baseline to the end of the trial.
24
25

26
27 Two consecutive 24h urine collections were made at baseline and at the end of the trial.
28
29 Participants were carefully instructed on how to accurately collect 24h urine and the
30
31 collections were supervised by trained research staff.^{8,9} In the event that the participant
32
33 reported to have missed one or more urine voids or spilt with an estimated spillage $>10\%$ of
34
35 the total 24h urine volume, this 24h urine collection was discarded and the participant was
36
37 asked to do a further 24h urine collection .
38
39

40
41 Ion-selective electrode method was used for urinary sodium analysis (AC9102 Electrolyte
42
43 Analyzer, Audicom Medical Technology Co., LTD) and Jaffe method for creatinine (Hitachi
44
45 7080 automatic biochemical analyzer, Japan). Urinary iodine was measured by the Key
46
47 Laboratory of Hormone and Development (Ministry of Health, China), that participated in the
48
49 US Centers for Disease Control and Prevention EQUIP (Ensuring the Quality of Urinary
50
51 Iodine Procedures) programme.¹⁰ Ammonium persulfate digestion with spectrophotometric
52
53 detection of the Sandell-Kolthoff reaction was used for urinary iodine measurement with
54
55 quality control.¹¹ For each batch of samples, we ran four levels of certified reference
56
57
58
59
60

1
2
3 material—lyophilized human urine (lot nos. GBW091081, GBW09110n, GBW09111a and
4
5 GBW09112a; National Reference Laboratory for iodine deficiency disorder, Beijing) with
6
7 mean certified iodine concentrations of 67.9 µg/L (95%CI: 58.9 to 76.9), 195µg/L (95%CI:
8
9 185 to 205), 558 µg/L (95%CI: 541 to 575) and 885 µg/L (95%CI: 857 to 913), respectively.

10
11
12 The biochemists who performed the urinary electrolyte and iodine measurements were not
13
14 aware which group the participant was allocated. The average of the two 24h urinary
15
16 measurements at each time point was used in the analysis.
17
18

19 20 **Project timeline**

21
22 The baseline assessments were carried out between late May and early July 2013, i.e. before
23
24 the schools' summer holiday. Randomisation took place during the summer holiday in
25
26 August. The intervention programme was carried out during the school term from September
27
28 to December. The follow-up assessments were carried out between late November and
29
30 December 2013.
31
32

33 34 **Statistical analyses**

35
36 As urinary iodine was not normally distributed, we used median and interquartile range (IQR)
37
38 to assess the iodine status. Three urine samples with iodine >5000 ug/24h were outliers and
39
40 excluded from the analysis. We used the cut-off points (EAR, estimated average requirement
41
42 and UL, tolerable upper limit) as recommended by the Chinese Nutrition Society¹² to define
43
44 iodine intake as insufficient if urinary iodine was less than EAR, i.e. <65 ug/24h in children
45
46 aged ≈10 or <85 ug/24h in adults; adequate if iodine was between EAR and UL, i.e. 65-300
47
48 ug/24h in children or 85-600 ug/24h in adults; excessive if urinary iodine was more than UL,
49
50 i.e. >300 in children or >600 ug/24h in adults. For the purpose of comparison with other
51
52 surveys, we also reported 24h urinary iodine concentration and iodine status based on urinary
53
54
55
56
57
58
59
60

1
2
3 iodine concentration according the WHO's criteria (i.e. iodine deficient <100 ug/L; adequate
4
5 100-199 ug/L, above requirement 200-299 ug/L; excessive \geq 300 ug/L).
6
7

8
9 Our main analysis was based on intention-to-treat. The mean effects of intervention on
10
11 outcomes including both salt and iodine were tested using linear mixed models with
12
13 participants nested within family units and families nested within school units. Logarithmic
14
15 transformed iodine was used, and as such, the mean effect on iodine was presented as
16
17 percentage change. We included group (intervention, control), time (baseline, end trial), and
18
19 time \times group interaction, with the time \times group interaction term indicating the mean effect. To
20
21 account for missing data on continuous outcomes, we used the likelihood-based random
22
23 effects model that uses all available data and provides valid estimates of the intervention
24
25 effects when data are missing at random. We adjusted for the stratification variables at
26
27 randomisation (school location and class size) and potential confounding variables including
28
29 age (continuous variable in children, categorical variable in adults \leq 40 years=1; 41-60
30
31 years=2; > 60 years=3), sex (male=0; female=1), body mass index (BMI), indoor and
32
33 outdoor temperature.
34
35
36
37

38
39 We carried out various sensitivity analyses to examine the robustness of the conclusions of
40
41 the primary analysis: (1) An analysis based on intention-to-treat approach, but excluding
42
43 possibly incomplete 24h urine collections defined as, in adults, urine volume was <500
44
45 mL/24h, or creatinine <4.0 mmol/24h for women or <6.0 mmol/24h for men¹³ and for
46
47 children, urine volume was <300 mL/24h¹⁴ or creatinine less than 5th percentile, i.e. <2.5
48
49 mmol/24h for girls and <2.9 mmol/24h for boys. (2) An analysis including only participants
50
51 who completed both baseline and end trial assessments (named as "completers"); (3) A per-
52
53 protocol analysis which included completers with complete 24h urine collections (i.e.
54
55 excluding possibly incomplete 24h urine collections). The number of 24h urine samples
56
57
58
59
60

1
2
3 included and excluded in each analysis was shown in Supplement Figure. If one of the two
4
5 24h urine collections was incomplete, only one was used in the sensitivity analysis.
6
7

8 We used SAS (version 9.4) for the analyses. Results are reported as mean, SD and 95% CI or
9
10 median and IQR where appropriate. All analyses were 2-sided and P values of <0.05 were
11
12 considered statistically significant.
13

14 **Results**

15
16
17 The School-EduSalt trial enrolled 279 children and 553 adults, all of whom were included in
18
19 the current report. The baseline characteristics of the participants were well balanced between
20
21 the intervention and the control group (Table 1). The mean age was 10.1 ± 0.5 years for
22
23 children and 43.8 ± 12.2 years for adults.
24

25
26 The result on salt has been published previously.⁹ We report it again in this paper explicitly
27
28 for the purpose of allowing the readers to compare the salt and iodine levels. At baseline, the
29
30 mean salt intake as calculated from 24h urinary sodium excretion was 7.0 ± 2.5 g/d in children
31
32 and 11.7 ± 4.4 g/d in adults. The median iodine consumption as measured by 24h urinary
33
34 iodine was $165.1 \mu\text{g/d}$ (IQR: 122.6-216.7, 95% CI: 156.9 to 172.9) and $280.7 \mu\text{g/d}$ (IQR:
35
36 205.1 - 380.9 , 95% CI: 270.3 to 293.8) in children and adults respectively.
37
38

39
40 Table 2 shows the salt and iodine intake by group, as well as their changes during the study.
41
42 From baseline to the end of the trial, both salt and iodine intake decreased in the intervention
43
44 group and increased in the control group. The mean effect size on salt for intervention vs
45
46 control was -1.9 g/d (95% CI: -2.6 to -1.3 , $P < 0.0001$) in children and -2.9 g/d (95% CI: -3.7
47
48 to -2.2 , $P < 0.0001$) in adults. The mean effect size on iodine was -19.3% (95% CI: -29.4% to
49
50 -7.7% , $P = 0.002$) in children and -11.4% (95% CI: -20.3% to -1.5% , $P = 0.03$) in adults.
51
52

53
54 Table 3 shows iodine status according to the Chinese Nutrition Society's guidelines.¹² In the
55
56 intervention group, there was an increase in the proportion of individuals with iodine intake
57
58
59
60

1
2
3 below EAR from baseline to the end of the trial. Despite this, there were only less than 5%
4 children and less than 3% adults who had iodine intake below EAR after salt intake was
5 reduced.
6
7
8

9
10 The results from sensitivity analyses are shown in Supplement Table 1. The first analysis
11 excluded possibly incomplete 24 urine collections. As expected, the absolute levels of salt
12 and iodine intake were higher compared with those when all 24h urine collections were
13 included. However, the primary outcome, i.e. the difference between the two groups in the
14 change of salt and iodine intake was very similar to that from the main analysis. The results
15 for completers and per-protocol analyses were very close to those from the corresponding
16 analyses with all participants included.
17
18
19
20
21
22
23
24

25
26 Supplement Table 2 shows the iodine status based on 24h urinary iodine concentration using
27 the WHO's criteria, as well as the median 24h urinary iodine concentration and the median
28 24h urinary iodine excretion for each category. In both children and adults, the median 24h
29 urinary iodine excretions in the group classified as iodine deficient according to the WHO's
30 criteria (i.e. <100 µg/L) were well above EAR across the study.
31
32
33
34
35
36
37
38

39 Discussion

40
41 Our study produced two important findings. First, the study for the first time has measured
42 iodine intake using repeat 24h urine collections in a large number of primary school children
43 and their families in northern China. A conservative estimate showed that the median
44 baseline iodine intake was 165 µg/d in children and 281 µg/d in adults. These intakes are
45 adequate. According to the Chinese Nutrition Society's guideline, EAR (i.e. daily intake
46 meeting the requirement of one-half of the population) is 65 µg/d in children aged 7-10 years
47 and 85 µg/d in adults, and RNI (recommended nutrient intake, i.e. intake meeting the
48 requirement of 97-98% of the population) is 90 µg/d in children aged 7-10 and 120 µg/d in
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 adults.¹² The median iodine intakes in our study were 254% and 331% of EAR, and 183%
4
5 and 234% of RNI for children and adults respectively. Additionally, the median iodine
6
7 intakes were far below the tolerable upper limit of 300 µg/d in children and 600 µg/d in
8
9 adults (Figure).

10
11
12 Second, our study is the first to have studied the effect of salt reduction, as currently
13
14 recommended, on iodine status in a population where salt is universally iodised. The mean
15
16 effect was a reduction in salt intake of 1.9 g/d in children and 2.9 g/d in adults which led to a
17
18 decrease in iodine intake of 19.3% and 11.4% in children and adults respectively. These
19
20 mean effects represent the differences between the intervention and control group in the
21
22 changes in salt and iodine from baseline to the end of the trial. As shown in table 2, during
23
24 the study, both salt and iodine intake decreased in the intervention group and increased in the
25
26 control group. If applying the mean reduction in iodine level (19.3% in children and 11.4% in
27
28 adults) to all participants irrespective of their group allocation, the average iodine intake
29
30 would be 133 µg/d in children and 249 µg/d in adults after salt reduction. These iodine levels
31
32 are still adequate, and 205% and 293% of EAR and 148% and 208% of RNI for children and
33
34 adults respectively.

35
36
37 In our study, all 24h urine collections were carefully supervised with both the start and finish
38
39 time recorded by trained research staff. It is certain that there was no over-collection.
40
41 However, it is difficult to know whether there was any under-collection. Although the
42
43 participants who admitted to having missed urine voids, were asked to re-do 24h urine
44
45 collections, it is still possible that some participants did not report missing urine collection.
46
47
48 Excluding potential incomplete 24h urine collections, as expected, led to a slightly higher salt
49
50 and iodine intake for both baseline and end trial, and for both the intervention and the control
51
52 group. It is therefore likely that our main results have under-estimated the average salt and
53
54
55
56
57
58
59
60

1
2
3 iodine intake of the study population. However, this is unlikely to alter the primary outcome,
4
5 i.e. the difference between the intervention and control group. Indeed, various sensitivity
6
7 analyses have shown consistent findings (Supplement Table 1).
8
9

10
11 In Changzhi where our study was carried out, the iodine content in salt varied from 18 to 33
12
13 mg/kg in 2013 (data was provided by the local salt manufacturer). Based on the iodine
14
15 content in salt and the 24h urinary sodium and iodine excretion, we estimated that
16
17 approximately 80% of iodine in the diet was from iodised salt. The changes in 24h urinary
18
19 iodine observed in our study is consistent with that predicted from the changes in salt intake
20
21 (Supplement Table 3 and 4). Therefore any potential influence from other dietary sources
22
23 would be small.
24
25

26
27 Despite 24h urinary iodine is the most reliable biochemical marker for assessing iodine
28
29 status, almost all previous surveys on iodine have used spot urine due to the apparent logistic
30
31 challenges and costs in collecting 24h urine. The WHO also endorsed the use of spot urine
32
33 and provided cut-offs of median spot urinary iodine concentration to categorise population's
34
35 iodine status.⁷ However, this has been inappropriately used by previous surveys to define the
36
37 number of individuals who were iodine deficient.¹⁵ Our study demonstrates that, in the group
38
39 of individuals classified as iodine deficient according to the WHO's criteria based on urinary
40
41 iodine concentration, the median 24h urinary iodine levels were well above EAR. These
42
43 findings clearly illustrate the inappropriateness of spot urine in monitoring iodine status and,
44
45 as a result, previous surveys would have over-estimated the prevalence of iodine deficiency.
46
47
48 It is worth noting that our study did not collect spot urine, however, 24h urinary iodine
49
50 concentration is a better index than any of the spot urine iodine concentration (e.g. casual,
51
52 first morning void). Additionally, our study shows that it is entirely feasible to collect 24h
53
54 urine not only in adults but also in primary school children. The WHO has recommended 24h
55
56
57
58
59
60

1
2
3 urine collections for determining and monitoring population salt intake.¹⁶ It will be more
4
5 efficient and highly cost-effective if the iodine intake is monitored in the same population
6
7 surveys using the same methods.
8
9

10
11 In China, since the introduction of universal salt iodisation in 1995, regular surveys using
12
13 casual spot urine have been carried out to monitor the population's iodine status and adjust
14
15 the iodine content in salt accordingly. The surveys were largely conducted in primary
16
17 schoolchildren aged 8-10 because these children are readily accessible in schools and they
18
19 have been assumed to have iodine intakes characteristic of general populations. At country
20
21 level, the median spot urinary iodine in schoolchildren aged 8-10 increased from 165 µg/L in
22
23 1995 to over 300 µg/L by 1999 and declined to 241 µg/L and 246 µg/L in 2002 and 2005,
24
25 respectively.¹⁷ This was in parallel with the changes of iodine content in salt which increased
26
27 from 16.2 mg/kg in 1995, to 42.3 mg/kg in 1999, then declined to 30.8 mg/kg in 2005 and
28
29 has remained at this level.¹⁷ These changes reflect the alterations of the standard for
30
31 'qualified' iodised salt set by the Chinese Ministry of Health.¹⁷ Initially the regulation for
32
33 iodine content was ≥ 20 mg/kg in 1995. As there was no upper limit, most salt producers
34
35 tended to iodise salt with iodine over 40 mg/kg. In 1997, an upper limit of 60 mg/kg was set.
36
37 National iodine survey at the time indicated an excessive population iodine intake and such
38
39 data led to a reduction in the upper limit from 60 to 50 mg/kg in 2002. The standard of 35±15
40
41 (or 20-50) mg/kg had remained till 2012 when provinces were allowed to choose from the
42
43 three standards, i.e. 20 (14-26), 25 (18-33) and 30 (21-39) mg/kg, depending on local diet and
44
45 spot urinary iodine concentration.¹⁸
46
47
48
49
50

51
52 In our study site—Changzhi, the changes in urinary iodine followed a similar pattern to that
53
54 occurred nationally although some of the surveys showed a higher iodine level. The most
55
56 recent survey in Changzhi was carried out in 2010 and showed that the median spot urinary
57
58
59
60

1
2
3 iodine was 241, 284 and 310 µg/L in schoolchildren aged 8, 9 and 10 respectively.¹⁹ In our
4
5 study which was done in 2013, the median baseline 24h urinary iodine concentration was
6
7 215.8 µg/L for schoolchildren aged ≈10 years. The lower iodine level observed in our study
8
9 could be largely due to the decrease in iodine content in salt following the change in the
10
11 standard for iodised salt (i.e. from 20-50 mg/kg to 18-33 mg/kg) in 2012.

12
13
14
15 Despite our study was carried out in Changzhi and included individuals who mainly ate
16
17 home-made meals, the results could be broadly applicable to most parts of China for the
18
19 following reasons: (1) Universal salt iodisation is mandatory in China, and the food
20
21 manufacturers and restaurants also use iodised salt; (2) The iodine content in salt (18-33
22
23 mg/kg) in Changzhi is similar to the national level (14-39 mg/kg)¹⁸; (3) Salt is the major
24
25 source of iodine in the diet across China. Although there is a variation in iodine level from
26
27 natural sources such as water and foods, iodised salt contributes to 60-80% of total iodine
28
29 intake in most parts of China.^{20 21} In Changzhi where our study was carried out, iodised salt
30
31 accounts for ≈80% of iodine intake (i.e. at the higher end of the range in China). The iodine
32
33 intake in our study population was still adequate after an approximate 25% reduction in salt
34
35 intake for 3.5 months, it is therefore most likely that the same reduction in salt if achieved
36
37 across China would not compromise iodine status.

38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Conclusions

Our study demonstrates that in northern China where universal salt iodisation is mandatory, a
reduction in salt intake by ≈25% which is close to the WHO's target of 30% reduction by
2025 does not compromise iodine status as measured by repeat 24h urinary iodine excretion
in both children and adults. These findings provide strong support for the WHO's
recommendations to reduce population salt intake to prevent hypertension and cardiovascular

1
2
3 disease, and to improve iodine intake by fortifying salt with iodine to prevent iodine
4
5 deficiency.
6
7

8
9 Currently many countries have started salt reduction initiatives and also implemented salt
10
11 iodisation programmes. However, there is a lack of coordination between the two. To
12
13 maximise the benefits, there is an urgent need for close coordination and collaboration,
14
15 particularly in disseminating consistent messages and monitoring population salt and iodine
16
17 intake using the same methods which will provide valuable data required for appropriate
18
19 adjustment of the iodine level in salt after population salt intake is reduced. This will be the
20
21 most cost-effective way in implementing the two important public health policies.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

We thank Peter Sever, Francesco Cappuccio, Kiang Liu, and Dong Zhao for their support and advice; the Changzhi Education Bureau, the headteachers and teachers of all participating schools, and children and their families who were involved in the research; all members of the field research team, particularly Jianhui Yuan, Yanbo Han, Peifen Duan, Zhifang Li, Jianbing Zhang, Cailing Wei, Yanli Zhai, Ruikai Zhu, Hui Yang, and Xiaoyun Wang; Jun Ma, Haijun Wang, Yide Yang, and Xiaorui Shang for their contribution and help with the development of the education materials; Yina Sun, Yan Ye, and Yongmei Li for their contribution to the measurement of urinary iodine.

Trial Steering Committee: Peter Sever (chair), Francesco Cappuccio, Kiang Liu, Dong Zhao, Feng He, Yangfeng Wu, and Graham MacGregor.

Contributors: FJH, YW and GAM designed the School-EduSalt trial. WZ developed the protocol for urinary iodine measurement and interpreted the iodine results. WZ, LL and XG organised urinary iodine measurement. JZ and YM performed quality control for iodine measurement. XF, JZ and YM contributed to data collection. FJH and YM developed the analysis plan, performed statistical analyses and took responsibility for the integrity of the data and the accuracy of the data analysis. FH wrote the manuscript. All authors contributed to the revision and approved the final manuscript. FJH is guarantor.

Funding: The School-EduSalt trial was funded by the UK Medical Research Council (MR/J015903/1) and it was part of the GACD (Global Alliance for Chronic Disease) Hypertension Programme. The measurement of iodine was funded by National Natural Science Foundation of China (81330064, 81273057). The funder of the study had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the article for publication.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare no financial relationships with any organisations that might have an interest in the submitted work in the previous three years. FJH is a member of Consensus Action on Salt & Health (CASH) and World Action on Salt & Health (WASH). Both CASH and WASH are non-profit charitable organisations and FJH does not receive any financial support from CASH or WASH. GAM is Chairman of Blood Pressure UK (BPUK), Chairman of CASH, WASH and Action on Sugar (AoS). BPUK, CASH, WASH and AoS are non-profit charitable organisations. GAM does not receive any financial support from any of these organisations. YM was sponsored by the China Scholarship Council while she was carrying out statistical analysis for this study at the Wolfson Institute of Preventive Medicine, Queen Mary University of London. Other authors declare that they have no conflicts of interest.

Ethical approval: The study protocol was approved by Queen Mary (University of London) Research Ethics Committee (QMREC2012/81) and Peking University Health Science Centre IRB (IRB00001052-12072). Permissions were obtained from the local education authority (i.e. Changzhi Education Bureau) and head-teachers of the schools. All participants who took part in the assessments gave written informed consent. For children, participant assent and parental written consent were obtained.

Data sharing: No additional data available.

REFERENCES

1. He FJ, MacGregor GA. Reducing population salt intake worldwide: from evidence to implementation. *Prog Cardiovasc Dis* 2010;52:363-82.
2. Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. *Lancet* 2007;370:2044-53.
3. National Institute for Health and Clinical Excellence (NICE). Guidance on the prevention of cardiovascular disease at the population level. <http://guidance.nice.org.uk/PH25>
4. WHO issues new guidance on dietary salt and potassium, 31 January 2013. http://www.who.int/mediacentre/news/notes/2013/salt_potassium_20130131/en/ (Accessed 10 May 2013)
5. Nath SK, Moinier B, Thuillier F, Rongier M, Desjeux JF. Urinary excretion of iodide and fluoride from supplemented food grade salt. *Int J Vitam Nutr Res* 1992;62:66-72.
6. Jahreis G, Hausmann W, Kiessling G, Franke K, Leiterer M. Bioavailability of iodine from normal diets rich in dairy products--results of balance studies in women. *Exp Clin Endocrinol Diabetes* 2001;109:163-7.
7. WHO 2014. Fortification of food-grade salt with iodine for the prevention and control of iodine deficiency disorders. Guideline http://www.who.int/nutrition/publications/guidelines/fortification_foodgrade_saltwithiodine/en/ (Accessed 27 January 2015).
8. He FJ, Wu Y, Ma J, Feng X, Wang H, Zhang J, et al. A school-based education programme to reduce salt intake in children and their families (School-EduSalt): protocol of a cluster randomised controlled trial. *BMJ Open* 2013;3:pii: e003388.
9. He FJ, Wu Y, Feng XX, Ma J, Ma Y, Wang H, et al. School based education programme to reduce salt intake in children and their families (School-EduSalt): cluster randomised controlled trial. *BMJ* 2015;350:h770.
10. Centres for Disease Control and Prevention (CDC). The Challenge of Iodine Deficiency Disorder. A Decade of CDC's Ensuring the Quality of Urinary Iodine Procedures Program www.cdc.gov/labstandards/pdf/equip/EQUIP_Booklet.pdf (Accessed 30 January 2015).
11. Zhang Y, Yan Y, Liu L, Sun Y, Li W, Hua J, et al. Revised method with low usage amount of arsenic trioxide for testing urinary iodine by As (III)-Ce⁴⁺ catalytic spectrophotometry using ammonium persulfate digestion. *Chin J Endemiol* 2013;32:95-100.
12. Chinese Nutrition Society, Chinese dietary reference intakes 2013, Science Press, 2014, Beijing, ISBN 978-7-03-041401-4.
13. Li N, Yan LL, Niu W, Labarthe D, Feng X, Shi J, et al. A large-scale cluster randomized trial to determine the effects of community-based dietary sodium reduction--the China Rural Health Initiative Sodium Reduction Study. *Am Heart J* 2013;166:815-22.
14. Maldonado-Martin A, Garcia-Matarin L, Gil-Extremuera B, Avivar-Oyonarte C, Garcia-Granados ME, Gil-Garcia F, et al. Blood pressure and urinary excretion of electrolytes in Spanish schoolchildren. *J Hum Hypertens* 2002;16:473-8.
15. Zimmermann MB, Andersson M. Assessment of iodine nutrition in populations: past, present, and future. *Nutr Rev* 2012;70:553-70.

- 1
2
3 16. WHO/PAHO Regional Expert Group for Cardiovascular Disease Prevention through
4 Population-wide Dietary Salt Reduction. Protocol for population level of sodium
5 determination in 24-hour urine samples
6 [http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=21488&I](http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=21488&Itemid)
7 [temid](http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=21488&Itemid) (accessed 21 July 2015).
8
- 9 17. Li S, Zheng Q, Xu J, Gorstein J, Wang H, Dong H. Iodine excess or not: analysis on the
10 necessity of reducing the iodine content in edible salt based on the national monitoring
11 results. *Asia Pac J Clin Nutr* 2011;20:501-6.
12
- 13 18. People's Republic of China National Standard. National food safety standards - Iodine
14 content in salt. GB 26878—2011. [http://www.shfda.gov.cn/spaqbz/GB26878-](http://www.shfda.gov.cn/spaqbz/GB26878-2011%20%E9%A3%9F%E7%94%A8%E7%9B%90%E7%A2%98%E5%90%AB%E9%87%8F.pdf)
15 [2011%20%E9%A3%9F%E7%94%A8%E7%9B%90%E7%A2%98%E5%90%AB%E9%](http://www.shfda.gov.cn/spaqbz/GB26878-2011%20%E9%A3%9F%E7%94%A8%E7%9B%90%E7%A2%98%E5%90%AB%E9%87%8F.pdf)
16 [87%8F.pdf](http://www.shfda.gov.cn/spaqbz/GB26878-2011%20%E9%A3%9F%E7%94%A8%E7%9B%90%E7%A2%98%E5%90%AB%E9%87%8F.pdf) (Accessed on 9 April 2015).
17
- 18 19. Guo WP, Chen CS, Duan HY. Analysis of urinary iodine result of 1208 children in
19 Changzhi. *Chinese Journal of Health Laboratory Technology* 2010;5:1173-74.
20
- 21 20. Wu Y, Li X, Chang S, Liu L, Zou S, Hipgrave DB. Variable iodine intake persists in the
22 context of universal salt iodization in China. *J Nutr* 2012;142:1728-34.
23
- 24 21. Song X, Li F, Liu Z, He Y, Sui H, Mao W, et al. Assessment of dietary iodine intake of
25 population in non-high-iodine areas in China. *Journal of Hygien Research* 2011;40:138-
26 41.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Legend to figure.** Mean salt, median iodine intake and their 95% confidence intervals in
4 children (A) and adults (B). EAR: Estimated average requirement; RNI: Recommended
5 nutrient intake; UL: Tolerable upper limit.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Baseline characteristics of the participants*

Parameters	Control	Intervention	All
Children			
Number of schools	14	14	28
Number of children	138	141	279
Boys, N (%)	67 (48.6)	67 (47.5)	134 (48.0)
Age (year)	10.2 (0.5)	10.0 (0.5)	10.1 (0.5)
Weight (kg)	33.3 (7.2)	33.4 (7.8)	33.3 (7.5)
Height (cm)	140.7 (6.6)	139.2 (6.2)	140.0 (6.5)
Body mass index (kg/m ²)	16.7 (2.7)	17.1 (3.2)	16.9 (3.0)
Adults			
Number of adults	275	278	553
Men, N (%)	133 (48.4)	135 (48.6)	268 (48.5)
Parents, N (%)	208 (75.6)	203 (73.0)	411 (74.3)
Grandparents, N (%)	67 (24.4)	75 (27.0)	142 (25.7)
Age (year)	43.6 (11.8)	43.9 (12.5)	43.8 (12.2)
Weight (kg)	66.2 (12.9)	66.1 (11.6)	66.2 (12.3)
Height (cm)	162.8 (8.7)	162.4 (8.0)	162.6 (8.4)
Body mass index (kg/m ²)	24.9 (3.6)	25.0 (3.4)	24.9 (3.5)

*Data are means (SD) unless otherwise specified.


Table 2. Salt and iodine intake as calculated from 24h urinary sodium and iodine excretion based on intention-to-treat analysis

Outcome	Control			Intervention			Mean effect† (intervention vs control)	P value
	Baseline*	End of trial*	Change from baseline*	Baseline*	End of trial*	Change from baseline*		
Children								
Salt, mean (95%CI) (g/d)	6.8 (6.2–7.4)	8.0 (7.4–8.6)	1.2 (0.7–1.7)	7.3 (6.7–7.9)	6.6 (6.0–7.2)	-0.7 (-1.2– -0.2)	-1.9 (-2.6– -1.3)	<0.0001
Iodine								
Geometric mean (95%CI) (µg/d)	162.8 (146.7–180.5)	187.5 (168.9–208.0)	115.2% (104.7%–126.7%)	173.7 (156.7–192.4)	163.2 (147.2–180.9)	94.0% (85.6%–103.2%)	-19.3% (-29.4%– -7.7%)	0.002
Median (IQR) (µg/d)	161.7 (117.7–209.5)	176.0 (136.5–237.2)	27.4 (-18.3–76.7)	167.0 (128.9–217.7)	154.8 (118.6–234.1)	-13.1 (-54.5–37.8)		
Adults								
Salt, mean (95%CI) (g/d)	11.3 (10.5–12.1)	12.1 (11.3–12.9)	0.8 (0.2–1.3)	12.6 (11.8–13.3)	10.4 (9.7–11.2)	-2.1 (-2.7– -1.6)	-2.9 (-3.7– -2.2)	<0.0001
Iodine								
Geometric mean (95%CI) (µg/d)	271.2 (245.1–300.1)	284.6 (256.9–315.2)	104.9% (97.2%–113.3%)	291.2 (263.3–322.1)	271.9 (245.7–301.0)	93.4% (86.6%–100.7%)	-11.4% (-20.3%– -1.5%)	0.030
Median (IQR) (µg/d)	262.1 (197.8–357.5)	281.3 (207.9–387.6)	10.7 (-72.8–105.3)	297.4 (213.2–390.8)	258.5 (199.8–350.0)	-36.5 (-128.4–88.9)		

* Mean and geometric mean were adjusted for stratification variables at randomisation (school location and class size). †Adjusted for age, sex, body mass index, stratification variables at randomisation (school location and class size), and indoor and outdoor temperature.

Table 3. Iodine status assessed by 24h urinary iodine excretion


Category	Control		Intervention	
	Baseline	End of trial	Baseline	End of trial
	N (%)	N (%)	N (%)	N (%)
Children				
<65 (µg/24h) (Estimated average requirement)	5 (3.62)	1 (0.74)	1 (0.71)	6 (4.32)
65-300 (µg/24h)	123 (89.13)	114 (84.44)	128 (90.78)	119 (85.61)
>300 (µg/24h) (Tolerable upper limit)	10 (7.25)	20 (14.81)	12 (8.51)	14 (10.07)
Adults				
<85 (µg/24h) (Estimated average requirement)	3 (1.09)	4 (1.53)	2 (0.72)	7 (2.58)
85-600 (µg/24h)	260 (94.55)	243 (93.10)	263 (94.95)	243 (89.67)
>600 (µg/24h) (Tolerable upper limit)	12 (4.36)	14 (5.36)	12 (4.33)	21 (7.75)



Mean salt, median iodine intake and their 95% confidence intervals in children (A) and adults (B). EAR: Estimated average requirement; RNI: Recommended nutrient intake; UL: Tolerable upper limit.

154x93mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Trial profile

20x26mm (600 x 600 DPI)

ONLINE SUPPLEMENT

Effect of salt reduction on iodine status assessed by 24h urinary iodine excretion in children and their families in northern China: a cluster randomised controlled trial

Feng J He,¹ Yuan Ma,^{1,2,3} Xiangxian Feng,⁴ Wanqi Zhang,^{5,6} Laixiang Lin,^{6,7} Xiaohui Guo,⁵ Jing Zhang,² Wenyi Niu,⁸ Yangfeng Wu,^{2,3,9}
Graham A MacGregor¹

¹ Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, UK.

² The George Institute for Global Health at Peking University Health Science Center, Beijing, China.

³ Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing, China.

⁴ Changzhi Medical College, Shanxi, China.

⁵ School of Public Health, Tianjin Medical University, Tianjin, China.

⁶ Key Laboratory of Hormone and Development (Ministry of Health), China.

⁷ Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.

⁸ Department of Social Medicine and Health Education, Peking University School of Public Health, Beijing, China.

⁹ Peking University Clinical Research Institute, Beijing, China.

Correspondence to:

Dr. Feng J He

Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London,
Charterhouse Square, London EC1M 6BQ.

Tel: +44 (0)20 7882 6266

Fax: +44 (0)20 7882 6270

E-mail: f.he@qmul.ac.uk

Professor Wanqi Zhang

School of Public Health, Tianjin Medical University, Tianjin, China. 300070

Tel: +86 (0)22 8333 6595

Fax: +86 (0)22 8333 6608

E-mail: wqzhang@tmu.edu.cn

Supplement Table 1. Sensitivity analysis for salt and iodine intake as calculated from 24h urinary sodium and iodine excretion

Outcome	Number of participant Control /Intervention	Control		Intervention		Adjusted difference (intervention vs control)	P value
		Baseline [‡]	Change from baseline [‡]	Baseline [‡]	Change from baseline [‡]		
Population excluding possibly incomplete 24h urine							
Children							
Salt (mean, 95%CI) (g/d)	138/140	7.0 (6.4–7.6)	1.2 (0.7–1.6)	7.5 (6.9–8.1)	-0.7 (-1.1 – -0.2)	-1.9 (-2.6– -1.2)	<0.0001
Iodine (geometric mean, 95%CI) (µg/d)	138/140	170.8 (155.0–188.2)	112.9% (102.7%–124.2%)	180.0 (163.6–198.1)	95.4% (86.9%–104.8%)	-16.5% (-26.9%– -4.6%)	0.008
Iodine (median, IQR) (µg/d)	138/140	166.5 (119.0–220.4)	27.3 (-20.6–79.0)	175.4 (131.3–228.7)	-9.3 (-52.4–39.0)		
Adults							
Salt (mean, 95%CI) (g/d)	273/275	11.6 (10.8–12.3)	0.8 (0.3–1.4)	12.8 (12.1–13.6)	-2.1 (-2.6– -1.6)	-3.0 (-3.7– -2.2)	<0.0001
Iodine (geometric mean, 95%CI) (µg/d)	273/275	280.7 (255.0–308.9)	104.6% (97.1%–112.7%)	298.0 (270.9–327.7)	95.6% (88.8%–102.9%)	-9.5% (-18.3%–0.2%)	0.055
Iodine (median, IQR) (µg/d)	273/275	275.7 (201.9–360.1)	15.1 (-78.3–105.3)	300.5 (219.2–392.5)	-30.2 (-117.7– 90.2)		
Completers*							
Children							
Salt (mean, 95%CI) (g/d)	135/139	6.8 (6.2–7.4)	1.2 (0.8–1.7)	7.2 (6.6–7.9)	-0.7 (-1.2– -0.2)	-1.9 (-2.6– -1.3)	<0.0001
Iodine (geometric mean, 95%CI) (µg/d)	135/139	162.0 (146.0–180.0)	115.4% (104.9%–126.9%)	173.5 (156.4–192.4)	94.0% (85.6%–103.2%)	-19.3% (-29.4%– -7.8%)	0.002

1								
2								
3	Iodine (median,							
4	IQR) (µg/d)	135/139	160.9 (117.7–208.1)	27.4 (-18.3–76.7)	169.6 (128.5–221.6)	-13.1 (-54.5–37.8)		
5								
6								
7								
8	Adults							
9	Salt (mean,							
10	95%CI) (g/d)	261/271	11.4 (10.6–12.1)	0.8 (0.2–1.3)	12.7 (11.9–13.5)	-2.2 (-2.7– -1.6)	-3.0 (-3.7– -2.2)	<0.0001
11	Iodine (geometric							
12	mean, 95%CI)	261/270	272.1 (245.3–301.7)	104.7% (96.9%–113.1%)	292.6 (264.1–324.3)	93.1% (86.3%–100.4%)	-11.1% (-20.1%– -1.1%)	0.030
13	(µg/d)							
14	Iodine (median,							
15	IQR) (µg/d)	261/270	261.8 (197.8–348.8)	10.7 (-72.8–105.3)	297.7 (213.2–391.8)	-36.5 (-128.4– 88.9)		
16								
17	Per protocol population†							
18								
19	Children							
20	Salt (mean,							
21	95%CI) (g/d)	132/137	7.0 (6.4–7.6)	1.2 (0.7–1.7)	7.5 (6.9–8.1)	-0.7 (-1.1– -0.2)	-1.9 (-2.6– -1.3)	<0.0001
22	Iodine (geometric							
23	mean, 95%CI)	132/137	169.5 (154.1–186.4)	114.1% (103.7%–125.5%)	179.6 (163.5–197.2)	95.9% (87.3%–105.3%)	-16.8% (-27.2%– -4.9%)	0.007
24	(µg/d)							
25	Iodine (median,							
26	IQR) (µg/d)	132/137	166.5 (120.3–216.8)	27.3 (-20.6–79.0)	178.8 (131.3–228.7)	-9.3 (-52.4–39.0)		
27								
28								
29	Adults							
30	Salt (mean,							
31	95%CI) (g/d)	249/256	11.6 (10.8–12.3)	0.9 (0.3–1.4)	12.9 (12.2–13.7)	-2.1 (-2.6– -1.6)	-3.0 (-3.7– -2.3)	<0.0001
32	Iodine (geometric							
33	mean, 95%CI)	249/255	282.4 (256.5–311.0)	104.3% (96.7%–112.5%)	296.3 (269.3–326.0)	96.1% (89.2%–103.6%)	-8.3% (-17.3%– -1.7%)	0.102
34	(µg/d)							
35	Iodine (median,							
36	IQR) (µg/d)	249/255	275.8 (203.1–360.1)	15.1 (-78.3–105.3)	300.1 (218.3–391.8)	-30.2 (-117.7– 90.2)		
37								

* Completers refer to the participants who had 24h urine collections both at baseline and the end of the trial. † Per protocol population refers to completers with complete 24h urine collections. ‡ Mean and geometric mean were adjusted for stratification variables at randomisation (school location and class size). § Adjusted for age, sex, body mass index, stratification variables at randomisation (school location and class size), and indoor and outdoor temperature.

Supplement Table 2. Iodine status assessed by 24h urinary iodine concentration using WHO's criteria, and median 24h urinary iodine concentration and 24h urinary iodine excretion for each category

Urinary iodine (µg/L)	Control						Intervention					
	Baseline			End of trial			Baseline			End of trial		
	N (%)	Iodine (median)		N (%)	Iodine (median)		N (%)	Iodine (median)		N (%)	Iodine (median)	
	(µg/L)	(µg/24h)		(µg/L)	(µg/24h)		(µg/L)	(µg/24h)		(µg/L)	(µg/24h)	
Children												
<100 (Iodine deficient)	10 (7.25)	85.07	94.93	10 (7.41)	84.26	114.51	5 (3.55)	86.17	89.84	11 (7.91)	86.65	113.78
100-199 (Adequate)	55 (39.86)	155.60	139.77	40 (29.63)	152.39	143.31	54 (38.30)	156.60	152.99	48 (34.53)	153.87	125.17
200-299 (Above requirement)	48 (34.78)	235.92	172.93	52 (38.52)	243.06	184.82	43 (30.50)	248.98	173.10	41 (29.5)	238.24	165.24
300 (Excessive)	25 (18.12)	430.84	249.11	33 (24.44)	371.52	279.42	39 (27.66)	357.28	236.15	39 (28.06)	411.03	260.88
ALL	138	204.60	161.70	135	222.50	176.0	141	225.30	167.00	139	217.10	154.80
Adults												
<100 (Iodine deficient)	32 (11.64)	81.31	137.25	38 (14.56)	72.84	149.13	31 (11.19)	79.49	140.35	48 (17.71)	74.71	164.03
100-199 (Adequate)	121 (44.00)	152.37	240.44	108 (41.38)	147.78	246.58	103 (37.18)	150.95	281.83	116 (42.80)	142.55	250.69
200-299 (Above requirement)	68 (24.73)	239.54	280.75	72 (27.59)	243.17	353.36	79 (28.52)	246.73	326.61	56 (20.66)	240.86	293.21
≥300 (Excessive)	54 (19.64)	372.08	420.86	43 (16.48)	351.76	460.61	64 (23.10)	372.21	423.84	51 (18.82)	364.22	535.18
ALL	275	188.80	262.10	261	183.60	281.3	277	209.4	297.40	271	176.20	258.5

Supplement Table 3. Comparison of iodine levels observed from 24h urinary iodine with that predicted from salt intake and iodine content in salt

	Control		Intervention	
	Baseline	End of trial	Baseline	End of trial
Children				
Observed from 24h urinary measurements				
Mean salt (g/d)	6.8	8.0	7.3	6.6
Median iodine (µg/d)	161.7	176.0	167.0	154.8
Predicted iodine based on salt intake and iodine content in salt using the minimum level of 18 mg/kg				
Predicted iodine (µg/d)	122.4	144.0	131.4	118.8
Ratio (predicted/observed)	0.8	0.8	0.8	0.8
Adults				
Observed from 24h urinary measurements				
Mean salt (g/d)	11.3	12.1	12.6	10.4
Median iodine (µg/d)	262.1	281.3	297.4	258.5
Predicted iodine based on salt intake and iodine content in salt using the minimum level of 18 mg/kg				
Predicted iodine (µg/d)	203.4	217.8	226.8	187.2
Ratio (predicted/observed)	0.8	0.8	0.8	0.7

Supplement Table 4. Salt and iodine intake, and iodine/salt ratio as calculated from 24h urinary sodium and iodine excretion

	Control		Intervention	
	Baseline	End of trial	Baseline	End of trial
Children				
Salt, mean (g/d)*	6.8	8.0	7.3	6.6
Iodine, median (µg/d)	161.7	176.0	167.0	154.8
Iodine/salt ratio, median (µg/g)	23.8	24.4	25.0	24.9
Adults				
Salt, mean (g/d)*	11.3	12.1	12.6	10.4
Iodine, median (µg/d)	262.1	281.3	297.4	258.5
Iodine/salt ratio, median (µg/g)	24.8	24.8	24.6	26.7

*adjusted for stratification variables at randomisation (school location and class size).



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2-3
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	5
	2b	Specific objectives or hypotheses	5
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	5-6
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	Not applicable
Participants	4a	Eligibility criteria for participants	6
	4b	Settings and locations where the data were collected	6
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	6-7
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	8-9
	6b	Any changes to trial outcomes after the trial commenced, with reasons	Not applicable
Sample size	7a	How sample size was determined	Not applicable
	7b	When applicable, explanation of any interim analyses and stopping guidelines	Not applicable
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	6
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	6
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	6
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	6
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	8

1			
2		assessing outcomes) and how	
3			
4		11b If relevant, description of the similarity of interventions	Not applicable
5	Statistical methods	12a Statistical methods used to compare groups for primary and secondary outcomes	8-9
6		12b Methods for additional analyses, such as subgroup analyses and adjusted analyses	9
7			
8	Results		
9	Participant flow (a	13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and	9-10 &
10	diagram is strongly	were analysed for the primary outcome	Supplement
11	recommended)		Figure
12		13b For each group, losses and exclusions after randomisation, together with reasons	9-10 &
13			Supplement
14			Figure
15			
16	Recruitment	14a Dates defining the periods of recruitment and follow-up	8
17		14b Why the trial ended or was stopped	Not applicable
18			
19	Baseline data	15 A table showing baseline demographic and clinical characteristics for each group	Table 1
20	Numbers analysed	16 For each group, number of participants (denominator) included in each analysis and whether the analysis was	Table 1 & 3,
21		by original assigned groups	Supplement
22			Figure
23			
24	Outcomes and	17a For each primary and secondary outcome, results for each group, and the estimated effect size and its	Table 2 & 3
25	estimation	precision (such as 95% confidence interval)	
26		17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended	Not applicable
27	Ancillary analyses	18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing	Supplement
28		pre-specified from exploratory	Table 1 & 2
29			
30	Harms	19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	Not applicable
31			
32	Discussion		
33	Limitations	20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	12-13
34	Generalisability	21 Generalisability (external validity, applicability) of the trial findings	15
35	Interpretation	22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	15-16
36			
37	Other information		
38	Registration	23 Registration number and name of trial registry	3
39	Protocol	24 Where the full trial protocol can be accessed, if available	6 &
40			Reference 8
41	Funding	25 Sources of funding and other support (such as supply of drugs), role of funders	17

1
2
3
4 *We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also
5 recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials.
6 Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

For peer review only

BMJ Open

Effect of salt reduction on iodine status assessed by 24h urinary iodine excretion in children and their families in northern China: a sub-study of a cluster randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-011168.R1
Article Type:	Research
Date Submitted by the Author:	28-Jun-2016
Complete List of Authors:	He, Feng; Queen Mary University of London, Wolfson Institute of Preventive Medicine Ma, Yuan; Peking University School of Public Health, Feng, Xiangxian; Changzhi Medical College Zhang, Wanqi; Tianjin Medical University Lin, Laixiang; Key Laboratory of Hormone and Development (Ministry of Health) Guo, Xiaohui; Tianjin Medical University Zhang, Jing; The George Institute for Global Health at Peking University Health Science Center, Niu, Wenyi; Peking University School of Public Health Wu, Yangfeng; The George Institute, MacGregor, Graham; Queen Mary University of London, Wolfson Institute of Preventive Medicine
Primary Subject Heading:	Public health
Secondary Subject Heading:	Nutrition and metabolism
Keywords:	Salt reduction, Iodine status, 24h urine collections, Cluster randomised trial

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Effect of salt reduction on iodine status assessed by 24h urinary iodine excretion in children and their families in northern China: a sub-study of a cluster randomised controlled trial

Feng J He,¹ Yuan Ma,^{1,2,3} Xiangxian Feng,⁴ Wanqi Zhang,^{5,6} Laixiang Lin,^{6,7} Xiaohui Guo,⁵ Jing Zhang,² Wenyi Niu,⁸ Yangfeng Wu,^{2,3,9} Graham A MacGregor¹

¹ Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, UK.

² The George Institute for Global Health at Peking University Health Science Center, Beijing, China.

³ Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing, China.

⁴ Changzhi Medical College, Shanxi, China.

⁵ School of Public Health, Tianjin Medical University, Tianjin, China.

⁶ Key Laboratory of Hormone and Development (Ministry of Health), China.

⁷ Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.

⁸ Department of Social Medicine and Health Education, Peking University School of Public Health, Beijing, China.

⁹ Peking University Clinical Research Institute, Beijing, China.

Running Title: Effect of salt reduction on iodine status

Correspondence to:

Dr. Feng J He

Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ.

Tel: +44 (0)20 7882 6266

Fax: +44 (0)20 7882 6270

E-mail: f.he@qmul.ac.uk

Professor Wanqi Zhang

School of Public Health, Tianjin Medical University, Tianjin, China. 300070

Tel: +86 (0)22 8333 6595

Fax: +86 (0)22 8333 6608

E-mail: wqzhang@tmu.edu.cn

Abstract

Objective To study the effect of salt reduction on iodine status and to determine whether iodine consumption was still adequate after salt intake was reduced in a population where universal salt iodisation is mandatory.

Design A sub-study of a cluster randomised controlled trial, where schools randomly assigned to either the intervention or control group.

Setting 28 primary schools in urban Changzhi, northern China.

Participants 279 children in grade 5 of primary school (mean age: 10.1); 553 adults (age: 43.8).

Intervention Children were educated about the harmful effects of salt and how to reduce salt intake using the schools' usual health education lessons. Children then delivered the message to their families. The duration was one school term (≈ 3.5 months).

Main outcome measure Difference between the intervention and control group in the change of iodine intake as measured by repeat 24h urinary iodine from baseline to the end of the trial.

Results At baseline, the mean salt intake was 7.0 ± 2.5 g/d in children and 11.7 ± 4.4 g/d in adults and the median iodine intake was $165.1 \mu\text{g/d}$ (IQR: 122.6-216.7) and $280.7 \mu\text{g/d}$ (IQR: 205.1-380.9) in children and adults respectively. At the end of the study, both salt and iodine decreased in the intervention compared with control group. The mean effect on salt for intervention vs control was -1.9 g/d (95% CI: -2.6 to -1.3) in children and -2.9 g/d (95% CI: -3.7 to -2.2) in adults. The mean effect on iodine was -19.3% (95% CI: -29.4% to -7.7%) in children and -11.4% (95% CI: -20.3% to -1.5%) in adults.

Conclusions With $\approx 25\%$ reduction in salt intake, there was a significant reduction in iodine consumption in northern China where salt is iodised. Despite this, iodine intake was

1
2
3 still adequate, and well above the estimated average requirement. Our findings indicate that
4
5 reducing salt to the WHO's target—30% reduction by 2025, will not compromise iodine
6
7 status.
8

9
10 **Trial registration** ClinicalTrials.gov NCT01821144.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- 24h urinary iodine excretion is the most reliable biochemical marker for assessing iodine status.
- Our study is the first to have assessed iodine status by repeat 24h urine collections in a large number of primary school children and their adult family members in northern China where universal salt iodisation is mandatory.
- Our study, for the first time, has assessed the effect of a modest reduction in salt intake on iodine status using a well-controlled randomised trial.
- The results demonstrate that $\approx 25\%$ reduction in salt intake which is close to the WHO's target, does not compromise iodine status.
- Despite all 24h urine collections followed stringent protocol with careful supervision, there might still be under collections in some participants. However, the consistent findings from various sensitivity analyses indicate that this is unlikely to alter the primary outcome.

Introduction

Iodine deficiency disorder is a global public health problem with approximately 1.88 billion people including 241 million school-age children having insufficient intake of iodine worldwide.¹ China was one of the countries that had serious epidemic of iodine deficiency disorders.² In 1993, the WHO (World Health Organisation) and UNICEF (United Nations Children's Fund) recommended universal salt iodization to prevent and control iodine deficiency.¹ China launched a universal salt iodisation programme in 1995.³ Since then a significant progress has been made in reducing iodine deficiency disorders.^{3,4} In recent years there has been debate about the optimal levels of iodine fortification in salt, particularly as salt intake is very high in China and iodine excess could also lead to thyroid diseases.^{3,5,6}

A reduction in salt intake is one of the most cost-effective public health policies to prevent hypertension and cardiovascular disease.⁷⁻⁹ The WHO recommends a 30% reduction in salt intake by 2025 for all countries around the world with an eventual target of 5 g/d.¹⁰ As salt has been used as a vehicle for iodine fortification in many countries, it is important to monitor iodine status to ensure that iodine consumption is still adequate when salt intake is reduced.

More than 90% of iodine consumed is excreted in the urine within 24-48 hours.^{11,12} Therefore, 24h urinary iodine excretion is a good marker of recent dietary iodine intake and is the ideal biochemical indicator for assessing iodine status.¹ We measured 24h urinary iodine excretion in individuals who took part in School-EduSalt (**School-based Education Programme to Reduce Salt**),^{13,14} a cluster randomised controlled trial in Changzhi, northern China where universal salt iodisation is mandatory. The primary aim of the School-EduSalt trial was to determine whether an education programme targeted at primary school children could lower salt intake in children and their families. The study collected two consecutive 24h urines at baseline and at the end of the trial using a standardised protocol with careful

1
2
3 supervision. The results showed that the education led to a significant reduction in salt intake
4
5 by approximately 25% in both children and adults compared with the controls. In this paper,
6
7 we report a pre-specified sub-study,¹⁵ the aim of which was to assess iodine status by repeat
8
9 24h urinary iodine excretion and to study the effect of salt reduction on iodine status, and in
10
11 particular to determine whether iodine consumption was still adequate after the participants
12
13 had been on a reduced salt intake for a few months.
14

15 16 17 **Methods**

18
19 A detailed description of the methods of the School-EduSalt study has been published
20
21 elsewhere^{13 14} and the abridged methods are reported here. The study was a cluster
22
23 randomised controlled trial in 28 primary schools in urban Changzhi, Northern China. From
24
25 each school, we selected one class in Grade 5 (age ≈10 years). From each class we randomly
26
27 selected 10 children who met the inclusion criteria.¹⁴ From each child's family we also
28
29 enrolled two adults. Schools were randomly assigned to either the intervention or the control
30
31 group with stratification by the location of schools and the size of the class.
32
33 Children in the intervention group were educated about the harmful effects of salt on health
34
35 and how to reduce salt intake using the schools' usual health education lessons, i.e. one 40
36
37 min lesson every two weeks.^{13 14} The salt reduction education was delivered to the whole
38
39 class in spite of only 10 children being selected for assessment. Children were asked to
40
41 deliver the salt reduction message to the families, particularly children needed to persuade the
42
43 persons who did the cooking to reduce the amount of salt used during food preparation at
44
45 home. The duration of the intervention was one school term (≈3.5 months). Children in the
46
47 control group carried on with their usual health education lessons as in the curriculum.
48
49 The primary outcome of this sub-study was the difference between the intervention and the
50
51 control group in the change of iodine intake as measured by 24h urinary iodine excretion
52
53 from baseline to the end of the trial.
54
55
56
57
58
59
60

Urinary iodine was measured by the Key Laboratory of Hormone and Development (Ministry of Health, China), that participated in the US Centers for Disease Control and Prevention EQUIP (Ensuring the Quality of Urinary Iodine Procedures) programme.¹⁶ Ammonium persulfate digestion with spectrophotometric detection of the Sandell-Kolthoff reaction was used for urinary iodine measurement with quality control.¹⁷ For each batch of samples, we ran four levels of certified reference material—lyophilized human urine (lot nos. GBW091081, GBW09110n, GBW09111a and GBW09112a; National Reference Laboratory for iodine deficiency disorder, Beijing) with mean certified iodine concentrations of 67.9 µg/L (95%CI: 58.9 to 76.9), 195 µg/L (95%CI: 185 to 205), 558 µg/L (95%CI: 541 to 575) and 885 µg/L (95%CI: 857 to 913), respectively. The biochemists who performed the urinary iodine measurements were not aware which group the participant was allocated.

Statistical analyses

As urinary iodine was not normally distributed, we used median and interquartile range (IQR) to summarise the iodine status. Three urine samples with iodine >5000 µg/24h were outliers and excluded from the analysis. We used the cut-off points (EAR, Estimated Average Requirement and UL, Tolerable Upper Limit) as recommended by the Chinese Nutrition Society¹⁸ to define iodine intake as insufficient if urinary iodine was less than EAR, i.e. <65 µg/24h in children aged ≈10 or <85 µg/24h in adults; adequate if iodine was between EAR and UL, i.e. 65-300 µg/24h in children or 85-600 µg/24h in adults; excessive if urinary iodine was more than UL, i.e. >300 µg/24h in children or >600 µg/24h in adults. For the purpose of comparison with other surveys, we also reported 24h urinary iodine concentration and iodine status based on urinary iodine concentration according the WHO's criteria (i.e. iodine deficient <100 µg/L; adequate 100-199 µg/L, above requirement 200-299 µg/L; excessive ≥300 µg/L).

Our main analysis was based on intention-to-treat using linear mixed models as reported previously.^{14 19} Logarithmic transformed iodine was used, and as such, the mean effect on iodine was presented as percentage change. The statistical model was in the form: Outcome= Group+Time+Interaction (time×group)+Stratification variables at randomisation (school location and class size)+Confounding variables (age, sex, body mass index, indoor and outdoor temperature). To examine the robustness of the conclusions of the primary analysis we carried out various sensitivity analyses as specified previously.¹⁴ The number of 24h urine samples included and excluded in each analysis was shown in Supplement Figure.

We used SAS (version 9.4) for the analyses. Results are reported as mean, SD and 95% CI or median and IQR where appropriate. All analyses were 2-sided and P values of <0.05 were considered statistically significant.

Results

The School-EduSalt trial enrolled 279 children and 553 adults, all of whom were included in the current report. The baseline characteristics of the participants were well balanced between the intervention and the control group (Supplement Table 1). The mean age was 10.1±0.5 years for children and 43.8±12.2 years for adults.

The result on salt has been published previously.¹⁴ We report it again in this paper explicitly for the purpose of allowing the readers to compare the salt and iodine levels. At baseline, the mean salt intake as calculated from 24h urinary sodium excretion was 7.0±2.5 g/d in children and 11.7±4.4 g/d in adults. The median iodine consumption as measured by 24h urinary iodine was 165.1 µg/d (IQR: 122.6-216.7, 95% CI: 156.9 to 172.9) and 280.7 µg/d (IQR: 205.1-380.9, 95% CI: 270.3 to 293.8) in children and adults respectively.

Table 1 shows the salt and iodine intake by group, as well as their changes during the study.

From baseline to the end of the trial, both salt and iodine intake decreased in the intervention

1
2
3 group and increased in the control group. The mean effect size on salt for intervention vs
4
5 control was -1.9 g/d (95% CI: -2.6 to -1.3, $P<0.0001$) in children and -2.9 g/d (95% CI: -3.7
6
7 to -2.2, $P<0.0001$) in adults. The mean effect size on iodine was -19.3% (95% CI: -29.4% to
8
9 -7.7%, $P=0.002$) in children and -11.4% (95% CI: -20.3% to -1.5%, $P=0.03$) in adults.

10
11 Table 2 shows iodine status according to the Chinese Nutrition Society's guidelines.¹⁸ In the
12
13 intervention group, there was an increase in the proportion of individuals with iodine intake
14
15 below EAR from baseline to the end of the trial. Despite this, there were only less than 5%
16
17 children and less than 3% adults who had iodine intake below EAR after salt intake was
18
19 reduced.

20
21 The results from sensitivity analyses are shown in Supplement Table 2. The first analysis
22
23 excluded possibly incomplete 24 urine collections. As expected, the absolute levels of salt
24
25 and iodine intake were higher compared with those when all 24h urine collections were
26
27 included. However, the primary outcome, i.e. the difference between the two groups in the
28
29 change of salt and iodine intake was very similar to that from the main analysis. The results
30
31 for completers (i.e. the participants who had 24h urine collections both at baseline and end of
32
33 the trial) and per-protocol analyses (including completers with complete 24h urine
34
35 collections) were very close to those from the corresponding analyses with all participants
36
37 included.

38
39 Supplement Table 3 shows the iodine status based on 24h urinary iodine concentration using
40
41 the WHO's criteria, as well as the median 24h urinary iodine concentration and the median
42
43 24h urinary iodine excretion for each category. In both children and adults, the median 24h
44
45 urinary iodine excretions in the group classified as iodine deficient according to the WHO's
46
47 criteria (i.e. <100 $\mu\text{g/L}$) were well above EAR across the study.

48 49 50 51 52 53 54 55 56 57 58 59 60

Discussion

1
2
3 Our study produced two important findings. First, the study for the first time has measured
4 iodine intake using repeat 24h urine collections in a large number of primary school children
5 and their families in northern China. A conservative estimate showed that the median
6 baseline iodine intake was 165 $\mu\text{g}/\text{d}$ in children and 281 $\mu\text{g}/\text{d}$ in adults. These intakes are
7 adequate. According to the Chinese Nutrition Society's guideline, EAR (i.e. daily intake
8 meeting the requirement of one-half of the population) is 65 $\mu\text{g}/\text{d}$ in children aged 7-10 years
9 and 85 $\mu\text{g}/\text{d}$ in adults, and RNI (recommended nutrient intake, i.e. intake meeting the
10 requirement of 97-98% of the population) is 90 $\mu\text{g}/\text{d}$ in children aged 7-10 and 120 $\mu\text{g}/\text{d}$ in
11 adults.¹⁸ The median iodine intakes in our study were 254% and 331% of EAR, and 183%
12 and 234% of RNI for children and adults respectively. Additionally, the median iodine
13 intakes were far below the tolerable upper limit of 300 $\mu\text{g}/\text{d}$ in children and 600 $\mu\text{g}/\text{d}$ in
14 adults (Figure).

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Second, our study is the first to have studied the effect of salt reduction, as currently
recommended, on iodine status in a population where salt is universally iodised. The mean
effect was a reduction in salt intake of 1.9 g/d in children and 2.9 g/d in adults which led to a
decrease in iodine intake of 19.3% and 11.4% in children and adults respectively. These
mean effects represent the differences between the intervention and control group in the
changes in salt and iodine from baseline to the end of the trial. As shown in table 1, during
the study, both salt and iodine intake decreased in the intervention group and increased in the
control group. If applying the mean reduction in iodine level (19.3% in children and 11.4% in
adults) to all participants irrespective of their group allocation, the average iodine intake
would be 133 $\mu\text{g}/\text{d}$ in children and 249 $\mu\text{g}/\text{d}$ in adults after salt reduction. These iodine levels
are still adequate, and 205% and 293% of EAR and 148% and 208% of RNI for children and
adults respectively.

1
2
3 In our study, all 24h urine collections were carefully supervised with both the start and finish
4 time recorded by trained research staff. It is certain that there was no over-collection.
5

6
7 However, it is difficult to know whether there was any under-collection. Although the
8 participants who admitted to having missed urine voids, were asked to re-do 24h urine
9 collections, it is still possible that some participants did not report missing urine collection.
10

11
12 Excluding potential incomplete 24h urine collections, as expected, led to a slightly higher salt
13 and iodine intake for both baseline and end trial, and for both the intervention and the control
14 group. It is therefore likely that our main results have under-estimated the average salt and
15 iodine intake of the study population. However, this is unlikely to alter the primary outcome,
16 i.e. the difference between the intervention and control group. Indeed, various sensitivity
17 analyses have shown consistent findings (Supplement Table 2).
18
19

20
21 In Changzhi where our study was carried out, the iodine content in salt varied from 18 to 33
22 mg/kg in 2013 (data was provided by the local salt manufacturer). Based on the iodine
23 content in salt and the 24h urinary sodium and iodine excretion, we estimated that ~80% of
24 iodine in the diet was from iodised salt. The changes in 24h urinary iodine observed in our
25 study is consistent with that predicted from the changes in salt intake (Supplement Table 4).
26
27 Therefore any potential influence from other dietary sources would be small.
28
29

30
31 Despite 24h urinary iodine is the most reliable biochemical marker for assessing iodine
32 status, almost all previous surveys on iodine have used spot urine due to the apparent logistic
33 challenges and costs in collecting 24h urine. The WHO also endorsed the use of spot urine
34 and provided cut-offs of median spot urinary iodine concentration to categorise population's
35 iodine status.¹ However, this has been inappropriately used by previous surveys to define the
36 number of individuals who were iodine deficient.²⁰ Our study demonstrates that, in the group
37 of individuals classified as iodine deficient according to the WHO's criteria based on urinary
38 iodine concentration, the median 24h urinary iodine levels were well above EAR. These
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 findings clearly illustrate the inappropriateness of spot urine in monitoring iodine status and,
4
5 as a result, previous surveys would have over-estimated the prevalence of iodine deficiency.
6
7 It is worth noting that our study did not collect spot urine, however, 24h urinary iodine
8
9 concentration is a better index than any of the spot urine iodine concentration (e.g. casual,
10
11 first morning void). Additionally, our study shows that it is entirely feasible to collect 24h
12
13 urine not only in adults but also in primary school children. The WHO has recommended 24h
14
15 urine collections for determining and monitoring population salt intake.²¹ It will be more
16
17 efficient and highly cost-effective if the iodine intake is monitored in the same population
18
19 surveys using the same methods.
20
21

22
23 In China, since the introduction of universal salt iodisation in 1995, regular surveys using
24
25 casual spot urine have been carried out to monitor the population's iodine status and adjust
26
27 the iodine content in salt accordingly.³ The surveys were largely conducted in primary
28
29 schoolchildren aged 8-10 because these children are readily accessible in schools and they
30
31 have been assumed to have iodine intakes characteristic of general populations. At country
32
33 level, the median spot urinary iodine in schoolchildren aged 8-10 increased from 165 µg/L in
34
35 1995 to over 300 µg/L by 1999 and declined to 241 µg/L and 246 µg/L in 2002 and 2005,
36
37 respectively.³ This was in parallel with the changes of iodine content in salt which increased
38
39 from 16.2 mg/kg in 1995, to 42.3 mg/kg in 1999, then declined to 30.8 mg/kg in 2005 and
40
41 has remained at this level.³ These changes reflect the alterations of the standard for
42
43 'qualified' iodised salt set by the Chinese Ministry of Health.³ Initially the regulation for
44
45 iodine content was ≥ 20 mg/kg in 1995. As there was no upper limit, most salt producers
46
47 tended to iodise salt with iodine over 40 mg/kg. In 1997, an upper limit of 60 mg/kg was set.
48
49 National iodine survey at the time indicated an excessive population iodine intake and such
50
51 data led to a reduction in the upper limit from 60 to 50 mg/kg in 2002. The standard of 35 ± 15
52
53 (or 20-50) mg/kg had remained till 2012 when provinces were allowed to choose from the
54
55
56
57
58
59
60

1
2
3 three standards, i.e. 20 (14-26), 25 (18-33) and 30 (21-39) mg/kg, depending on local diet and
4
5 spot urinary iodine concentration.²²
6

7
8 In our study site—Changzhi, the changes in urinary iodine followed a similar pattern to that
9
10 occurred nationally although some of the surveys showed a higher iodine level. The most
11
12 recent survey in Changzhi was carried out in 2010 and showed that the median spot urinary
13
14 iodine was 241, 284 and 310 µg/L in schoolchildren aged 8, 9 and 10 respectively.²³ In our
15
16 study which was done in 2013, the median baseline 24h urinary iodine concentration was
17
18 215.8 µg/L for schoolchildren aged ≈10 years. The lower iodine level observed in our study
19
20 could be largely due to the decrease in iodine content in salt following the change in the
21
22 standard for iodised salt (i.e. from 20-50 mg/kg to 18-33 mg/kg) in 2012.
23

24
25 Despite our study was carried out in Changzhi and included individuals who mainly ate
26
27 home-made meals, the results could be broadly applicable to most parts of China for the
28
29 following reasons: (1) Universal salt iodisation is mandatory in China, and the food
30
31 manufacturers and restaurants also use iodised salt; (2) The iodine content in salt (18-33
32
33 mg/kg) in Changzhi is similar to the national level (14-39 mg/kg)²²; (3) Salt is the major
34
35 source of iodine in the diet across China. Although there is a variation in iodine level from
36
37 natural sources such as water and foods, iodised salt contributes to 60-80% of total iodine
38
39 intake in most parts of China.^{24 25} In Changzhi where our study was carried out, iodised salt
40
41 accounts for ≈80% of iodine intake (i.e. at the higher end of the range in China). The iodine
42
43 intake in our study population was still adequate after an approximate 25% reduction in salt
44
45 intake for 3.5 months, it is therefore most likely that the same reduction in salt if achieved
46
47 across China would not compromise iodine status. The findings of our study, however, may
48
49 not be generalisable to populations in other countries due to a number of features in the
50
51 setting, such as universal salt iodisation and high contribution of discretionary salt to total salt
52
53 intake in the Chinese diet.
54
55
56
57
58
59
60

Conclusions

Our study demonstrates that in northern China where universal salt iodisation is mandatory, a reduction in salt intake by $\approx 25\%$ which is close to the WHO's target of 30% reduction by 2025 does not compromise iodine status as measured by repeat 24h urinary iodine excretion in both children and adults. These findings provide strong support for the WHO's recommendations to reduce population salt intake to prevent hypertension and cardiovascular disease, and to improve iodine intake by fortifying salt with iodine to prevent iodine deficiency.

Currently many countries have started salt reduction initiatives and also implemented salt iodisation programmes.²⁶ However, there is a lack of coordination between the two. To maximise the benefits, there is an urgent need for close coordination and collaboration, particularly in disseminating consistent messages and monitoring population salt and iodine intake using the same methods which will provide valuable data required for appropriate adjustment of the iodine level in salt after population salt intake is reduced. This will be the most cost-effective way in implementing the two important public health policies.

Acknowledgements

We thank Peter Sever, Francesco Cappuccio, Kiang Liu, and Dong Zhao for their support and advice; the Changzhi Education Bureau, the headteachers and teachers of all participating schools, and children and their families who were involved in the research; all members of the field research team, particularly Jianhui Yuan, Yanbo Han, Peifen Duan, Zhifang Li, Jianbing Zhang, Cailing Wei, Yanli Zhai, Ruikai Zhu, Hui Yang, and Xiaoyun Wang; Jun Ma, Haijun Wang, Yide Yang, and Xiaorui Shang for their contribution and help with the development of the education materials; Yina Sun, Yan Ye, and Yongmei Li for their contribution to the measurement of urinary iodine.

Trial Steering Committee: Peter Sever (chair), Francesco Cappuccio, Kiang Liu, Dong Zhao, Feng He, Yangfeng Wu, and Graham MacGregor.

Contributors: FJH, YW and GAM designed the School-EduSalt trial. WZ developed the protocol for urinary iodine measurement and interpreted the iodine results. WZ, LL and XG organised urinary iodine measurement. JZ and YM performed quality control for iodine measurement. XF, JZ and YM contributed to data collection. FJH and YM developed the analysis plan, performed statistical analyses and took responsibility for the integrity of the data and the accuracy of the data analysis. FH wrote the manuscript. All authors contributed to the revision and approved the final manuscript. FJH is guarantor.

Funding: The School-EduSalt trial was funded by the UK Medical Research Council (MR/J015903/1) and it was part of the GACD (Global Alliance for Chronic Disease) Hypertension Programme. The measurement of iodine was funded by National Natural Science Foundation of China (81330064, 81273057). The funder of the study had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the article for publication.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare no financial relationships with any organisations that might have an interest in the submitted work in the previous three years. FJH is a member of Consensus Action on Salt & Health (CASH) and World Action on Salt & Health (WASH). Both CASH and WASH are non-profit charitable organisations and FJH does not receive any financial support from CASH or WASH. GAM is Chairman of Blood Pressure UK (BPUK), Chairman of CASH, WASH and Action on Sugar (AoS). BPUK, CASH, WASH and AoS are non-profit charitable organisations. GAM does not receive any financial support from any of these organisations. YM was sponsored by the China Scholarship Council while she was carrying out statistical analysis for this study at the Wolfson Institute of Preventive Medicine, Queen Mary University of London. Other authors declare that they have no conflicts of interest.

Ethical approval: The study protocol was approved by Queen Mary (University of London) Research Ethics Committee (QMREC2012/81) and Peking University Health Science Centre IRB (IRB00001052-12072). Permissions were obtained from the local education authority (i.e. Changzhi Education Bureau) and head-teachers of the schools. All participants who took part in the assessments gave written informed consent. For children, participant assent and parental written consent were obtained.

Data sharing: No additional data available.

REFERENCES

1. WHO 2014. Fortification of food-grade salt with iodine for the prevention and control of iodine deficiency disorders. Guideline http://www.who.int/nutrition/publications/guidelines/fortification_foodgrade_saltwithiodine/en/ (Accessed 27 January 2015).
2. Ma T, Guo J, Wang F. The epidemiology of iodine-deficiency diseases in China. *Am J Clin Nutr* 1993;57:264S-66S.
3. Li S, Zheng Q, Xu J, Gorstein J, Wang H, Dong H. Iodine excess or not: analysis on the necessity of reducing the iodine content in edible salt based on the national monitoring results. *Asia Pac J Clin Nutr* 2011;20:501-6.
4. Pearce EN, Andersson M, Zimmermann MB. Global iodine nutrition: Where do we stand in 2013? *Thyroid* 2013;23:523-8.
5. Teng W, Shan Z, Teng X, Guan H, Li Y, Teng D, et al. Effect of iodine intake on thyroid diseases in China. *N Engl J Med* 2006;354:2783-93.
6. Sang Z, Wang PP, Yao Z, Shen J, Halfyard B, Tan L, et al. Exploration of the safe upper level of iodine intake in euthyroid Chinese adults: a randomized double-blind trial. *Am J Clin Nutr* 2012;95:367-73.
7. He FJ, MacGregor GA. Reducing population salt intake worldwide: from evidence to implementation. *Prog Cardiovasc Dis* 2010;52:363-82.
8. Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. *Lancet* 2007;370:2044-53.
9. National Institute for Health and Clinical Excellence (NICE). Guidance on the prevention of cardiovascular disease at the population level. <http://guidance.nice.org.uk/PH25>
10. WHO issues new guidance on dietary salt and potassium, 31 January 2013. http://www.who.int/mediacentre/news/notes/2013/salt_potassium_20130131/en/
11. Nath SK, Moinier B, Thuillier F, Rongier M, Desjeux JF. Urinary excretion of iodide and fluoride from supplemented food grade salt. *Int J Vitam Nutr Res* 1992;62:66-72.
12. Jahreis G, Hausmann W, Kiessling G, Franke K, Leiterer M. Bioavailability of iodine from normal diets rich in dairy products--results of balance studies in women. *Exp Clin Endocrinol Diabetes* 2001;109:163-7.
13. He FJ, Wu Y, Ma J, Feng X, Wang H, Zhang J, et al. A school-based education programme to reduce salt intake in children and their families (School-EduSalt): protocol of a cluster randomised controlled trial. *BMJ Open* 2013;3:pii: e003388.
14. He FJ, Wu Y, Feng XX, Ma J, Ma Y, Wang H, et al. School based education programme to reduce salt intake in children and their families (School-EduSalt): cluster randomised controlled trial. *BMJ* 2015;350:h770.
15. He FJ, Ma Y, Feng X, Zhang W, Lin L, Guo X, et al. Effect of salt reduction on iodine status in children and their families in northern China: a sub-study of a cluster-randomised controlled trial. *Lancet* 2015;386:34.
16. Centres for Disease Control and Prevention (CDC). The Challenge of Iodine Deficiency Disorder. A Decade of CDC's Ensuring the Quality of Urinary Iodine Procedures Program www.cdc.gov/labstandards/pdf/equip/EQUIP_Booklet.pdf (Accessed 30 January 2015).

- 1
2
3 17. Zhang Y, Yan Y, Liu L, Sun Y, Li W, Hua J, et al. Revised method with low usage
4 amount of arsenic trioxide for testing urinary iodine by As (III)-Ce⁴⁺ catalytic
5 spectrophotometry using ammonium persulfate digestion. *Chin J Endemiol* 2013;32:95-
6 100.
7
8 18. Chinese Nutrition Society, Chinese dietary reference intakes 2013, Science Press,
9 2014, Beijing, ISBN 978-7-03-041401-4.
10
11 19. Carpenter JR, Kenward MG. Missing data in randomised controlled trials-a practical
12 guide. London School of Hygiene.
13 2007:[https://www.researchgate.net/publication/228754654_Missing_Data_in_Randomise](https://www.researchgate.net/publication/228754654_Missing_Data_in_Randomised_Controlled_Trials-A_Practical_Guide)
14 [d_Controlled_Trials-A_Practical_Guide](https://www.researchgate.net/publication/228754654_Missing_Data_in_Randomised_Controlled_Trials-A_Practical_Guide) (Accessed 14 June 2016).
15
16 20. Zimmermann MB, Andersson M. Assessment of iodine nutrition in populations: past,
17 present, and future. *Nutr Rev* 2012;70:553-70.
18
19 21. WHO/PAHO Regional Expert Group for Cardiovascular Disease Prevention through
20 Population-wide Dietary Salt Reduction. Protocol for population level of sodium
21 determination in 24-hour urine samples
22 [http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=21488&I](http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=21488&Itemid)
23 [temid](http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=21488&Itemid) (accessed 21 July 2015).
24
25 22. People's Republic of China National Standard. National food safety standards - Iodine
26 content in salt. GB 26878—2011. [http://www.shfda.gov.cn/spaqbz/GB26878-](http://www.shfda.gov.cn/spaqbz/GB26878-2011%20%E9%A3%9F%E7%94%A8%E7%9B%90%E7%A2%98%E5%90%AB%E9%87%8F.pdf)
27 [2011%20%E9%A3%9F%E7%94%A8%E7%9B%90%E7%A2%98%E5%90%AB%E9%](http://www.shfda.gov.cn/spaqbz/GB26878-2011%20%E9%A3%9F%E7%94%A8%E7%9B%90%E7%A2%98%E5%90%AB%E9%87%8F.pdf)
28 [87%8F.pdf](http://www.shfda.gov.cn/spaqbz/GB26878-2011%20%E9%A3%9F%E7%94%A8%E7%9B%90%E7%A2%98%E5%90%AB%E9%87%8F.pdf) (Accessed on 9 April 2015).
29
30 23. Guo WP, Chen CS, Duan HY. Analysis of urinary iodine result of 1208 children in
31 Changzhi. *Chinese Journal of Health Laboratory Technology* 2010;5:1173-74.
32
33 24. Wu Y, Li X, Chang S, Liu L, Zou S, Hipgrave DB. Variable iodine intake persists in the
34 context of universal salt iodization in China. *J Nutr* 2012;142:1728-34.
35
36 25. Song X, Li F, Liu Z, He Y, Sui H, Mao W, et al. Assessment of dietary iodine intake of
37 population in non-high-iodine areas in China. *Journal of Hygien Research* 2011;40:138-
38 41.
39
40 26. Campbell NR, Dary O, Cappuccio FP, Neufeld LM, Harding KB, Zimmermann MB.
41 Need for coordinated programs to improve global health by optimizing salt and iodine
42 intake. *Rev Panam Salud Publica* 2012;32:281-6.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Legend to figure.** Mean salt, median iodine intake and their 95% confidence intervals in
4 children (A) and adults (B). EAR: Estimated average requirement; RNI: Recommended
5 nutrient intake; UL: Tolerable upper limit.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


Table 1. Salt and iodine intake as calculated from 24h urinary sodium and iodine excretion based on intention-to-treat analysis

Outcome	Control			Intervention			Mean effect† (intervention vs control)	P value
	Baseline*	End of trial*	Change from baseline*	Baseline*	End of trial*	Change from baseline*		
Children								
Salt, mean‡ (95%CI) (g/d)	6.8 (6.2–7.4)	8.0 (7.4–8.6)	1.2 (0.7–1.7)	7.3 (6.7–7.9)	6.6 (6.0–7.2)	-0.7 (-1.2– -0.2)	-1.9 (-2.6– -1.3)	<0.0001
Iodine								
Geometric mean (95%CI) (µg/d)	162.8 (146.7–180.5)	187.5 (168.9–208.0)	115.2% (104.7%–126.7%)	173.7 (156.7–192.4)	163.2 (147.2–180.9)	94.0% (85.6%–103.2%)	-19.3% (-29.4%– -7.7%)	0.002
Median (IQR) (µg/d)	161.7 (117.7–209.5)	176.0 (136.5–237.2)	27.4 (-18.3–76.7)	167.0 (128.9–217.7)	154.8 (118.6–234.1)	-13.1 (-54.5–37.8)		
Adults								
Salt, mean (95%CI) (g/d)	11.3 (10.5–12.1)	12.1 (11.3–12.9)	0.8 (0.2–1.3)	12.6 (11.8–13.3)	10.4 (9.7–11.2)	-2.1 (-2.7– -1.6)	-2.9 (-3.7– -2.2)	<0.0001
Iodine								
Geometric mean (95%CI) (µg/d)	271.2 (245.1–300.1)	284.6 (256.9–315.2)	104.9% (97.2%–113.3%)	291.2 (263.3–322.1)	271.9 (245.7–301.0)	93.4% (86.6%–100.7%)	-11.4% (-20.3%– -1.5%)	0.030
Median (IQR) (µg/d)	262.1 (197.8–357.5)	281.3 (207.9–387.6)	10.7 (-72.8–105.3)	297.4 (213.2–390.8)	258.5 (199.8–350.0)	-36.5 (-128.4–88.9)		

* Mean and geometric mean were adjusted for stratification variables at randomisation (school location and class size). †Adjusted for age, sex, body mass index, stratification variables at randomisation (school location and class size), and indoor and outdoor temperature. ‡The results for salt were taken from previous report.¹⁴

Table 2. Iodine status assessed by 24h urinary iodine excretion

Category	Control		Intervention	
	Baseline	End of trial	Baseline	End of trial
	N (%)	N (%)	N (%)	N (%)
Children				
<65 (µg/d) (Estimated average requirement)	5 (3.62)	1 (0.74)	1 (0.71)	6 (4.32)
65-300 (µg/d)	123 (89.13)	114 (84.44)	128 (90.78)	119 (85.61)
>300 (µg/d) (Tolerable upper limit)	10 (7.25)	20 (14.81)	12 (8.51)	14 (10.07)
Adults				
<85 (µg/d) (Estimated average requirement)	3 (1.09)	4 (1.53)	2 (0.72)	7 (2.58)
85-600 (µg/d)	260 (94.55)	243 (93.10)	263 (94.95)	243 (89.67)
>600 (µg/d) (Tolerable upper limit)	12 (4.36)	14 (5.36)	12 (4.33)	21 (7.75)




Mean salt, median iodine intake and their 95% confidence intervals in children (A) and adults (B). EAR: Estimated average requirement; RNI: Recommended nutrient intake; UL: Tolerable upper limit.

93x57mm (300 x 300 DPI)

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Trial profile

233x307mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ONLINE SUPPLEMENT

Effect of salt reduction on iodine status assessed by 24h urinary iodine excretion in children and their families in northern China: a sub-study of a cluster randomised controlled trial

Feng J He,¹ Yuan Ma,^{1,2,3} Xiangxian Feng,⁴ Wanqi Zhang,^{5,6} Laixiang Lin,^{6,7} Xiaohui Guo,⁵ Jing Zhang,² Wenyi Niu,⁸ Yangfeng Wu,^{2,3,9}
Graham A MacGregor¹

¹ Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, UK.

² The George Institute for Global Health at Peking University Health Science Center, Beijing, China.

³ Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing, China.

⁴ Changzhi Medical College, Shanxi, China.

⁵ School of Public Health, Tianjin Medical University, Tianjin, China.

⁶ Key Laboratory of Hormone and Development (Ministry of Health), China.

⁷ Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.

⁸ Department of Social Medicine and Health Education, Peking University School of Public Health, Beijing, China.

⁹ Peking University Clinical Research Institute, Beijing, China.

Correspondence to:

Dr. Feng J He

Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London,
Charterhouse Square, London EC1M 6BQ.

Tel: +44 (0)20 7882 6266

Fax: +44 (0)20 7882 6270

E-mail: f.he@qmul.ac.uk

Professor Wanqi Zhang

School of Public Health, Tianjin Medical University, Tianjin, China. 300070

Tel: +86 (0)22 8333 6595

Fax: +86 (0)22 8333 6608

E-mail: wqzhang@tmu.edu.cn

Supplement Table 1. Baseline characteristics of the participants*

Parameters	Control	Intervention	All
Children			
Number of schools	14	14	28
Number of children	138	141	279
Boys, N (%)	67 (48.6)	67 (47.5)	134 (48.0)
Age (year)	10.2 (0.5)	10.0 (0.5)	10.1 (0.5)
Weight (kg)	33.3 (7.2)	33.4 (7.8)	33.3 (7.5)
Height (cm)	140.7 (6.6)	139.2 (6.2)	140.0 (6.5)
Body mass index (kg/m ²)	16.7 (2.7)	17.1 (3.2)	16.9 (3.0)
Adults			
Number of adults	275	278	553
Men, N (%)	133 (48.4)	135 (48.6)	268 (48.5)
Parents, N (%)	208 (75.6)	203 (73.0)	411 (74.3)
Grandparents, N (%)	67 (24.4)	75 (27.0)	142 (25.7)
Age (year)	43.6 (11.8)	43.9 (12.5)	43.8 (12.2)
Weight (kg)	66.2 (12.9)	66.1 (11.6)	66.2 (12.3)
Height (cm)	162.8 (8.7)	162.4 (8.0)	162.6 (8.4)
Body mass index (kg/m ²)	24.9 (3.6)	25.0 (3.4)	24.9 (3.5)

*Data are means (SD) unless otherwise specified.

Supplement Table 2. Sensitivity analysis for salt and iodine intake as calculated from 24h urinary sodium and iodine excretion

Outcome	Number of participant Control /Intervention	Control		Intervention		Adjusted difference (intervention vs control)	P value
		Baseline [‡]	Change from baseline [‡]	Baseline [‡]	Change from baseline [‡]		
Population excluding possibly incomplete 24h urine							
Children							
Salt (mean, 95%CI) (g/d)	138/140	7.0 (6.4–7.6)	1.2 (0.7–1.6)	7.5 (6.9–8.1)	-0.7 (-1.1 – -0.2)	-1.9 (-2.6– -1.2)	<0.0001
Iodine (geometric mean, 95%CI) (µg/d)	138/140	170.8 (155.0–188.2)	112.9% (102.7%–124.2%)	180.0 (163.6–198.1)	95.4% (86.9%–104.8%)	-16.5% (-26.9%– -4.6%)	0.008
Iodine (median, IQR) (µg/d)	138/140	166.5 (119.0–220.4)	27.3 (-20.6–79.0)	175.4 (131.3–228.7)	-9.3 (-52.4–39.0)		
Adults							
Salt (mean, 95%CI) (g/d)	273/275	11.6 (10.8–12.3)	0.8 (0.3–1.4)	12.8 (12.1–13.6)	-2.1 (-2.6–-1.6)	-3.0 (-3.7– -2.2)	<0.0001
Iodine (geometric mean, 95%CI) (µg/d)	273/275	280.7 (255.0–308.9)	104.6% (97.1%–112.7%)	298.0 (270.9–327.7)	95.6% (88.8%–102.9%)	-9.5% (-18.3%–0.2%)	0.055
Iodine (median, IQR) (µg/d)	273/275	275.7 (201.9–360.1)	15.1 (-78.3–105.3)	300.5 (219.2–392.5)	-30.2 (-117.7–90.2)		
Completers*							
Children							
Salt (mean, 95%CI) (g/d)	135/139	6.8 (6.2–7.4)	1.2 (0.8–1.7)	7.2 (6.6–7.9)	-0.7 (-1.2– -0.2)	-1.9 (-2.6– -1.3)	<0.0001
Iodine (geometric mean, 95%CI) (µg/d)	135/139	162.0 (146.0–180.0)	115.4% (104.9%–126.9%)	173.5 (156.4–192.4)	94.0% (85.6%–103.2%)	-19.3% (-29.4%– -7.8%)	0.002

1	Iodine (median,		160.9	27.4	169.6	-13.1		
2	IQR) (µg/d)	135/139	(117.7–208.1)	(-18.3–76.7)	(128.5–221.6)	(-54.5–37.8)		
3								
4								
5								
6	Adults							
7	Salt (mean,		11.4	0.8	12.7	-2.2	-3.0	<0.0001
8	95%CI) (g/d)	261/271	(10.6–12.1)	(0.2–1.3)	(11.9–13.5)	(-2.7– -1.6)	(-3.7– -2.2)	
9	Iodine (geometric		272.1	104.7%	292.6	93.1%	-11.1%	0.030
10	mean, 95%CI)	261/270	(245.3–301.7)	(96.9%–113.1%)	(264.1–324.3)	(86.3%–100.4%)	(-20.1%– -1.1%)	
11	(µg/d)							
12	Iodine (median,		261.8	10.7	297.7	-36.5		
13	IQR) (µg/d)	261/270	(197.8–348.8)	(-72.8–105.3)	(213.2–391.8)	(-128.4– 88.9)		
14								
15								
16	Per protocol population†							
17								
18	Children							
19	Salt (mean,		7.0	1.2	7.5	-0.7	-1.9	<0.0001
20	95%CI) (g/d)	132/137	(6.4–7.6)	(0.7–1.7)	(6.9–8.1)	(-1.1– -0.2)	(-2.6– -1.3)	
21	Iodine (geometric		169.5	114.1%	179.6	95.9%	-16.8%	0.007
22	mean, 95%CI)	132/137	(154.1–186.4)	(103.7%–125.5%)	(163.5–197.2)	(87.3%–105.3%)	(-27.2%– -4.9%)	
23	(µg/d)							
24	Iodine (median,		166.5	27.3	178.8	-9.3		
25	IQR) (µg/d)	132/137	(120.3–216.8)	(-20.6–79.0)	(131.3–228.7)	(-52.4–39.0)		
26								
27								
28	Adults							
29	Salt (mean,		11.6	0.9	12.9	-2.1	-3.0	<0.0001
30	95%CI) (g/d)	249/256	(10.8–12.3)	(0.3–1.4)	(12.2–13.7)	(-2.6– -1.6)	(-3.7– -2.3)	
31	Iodine (geometric		282.4	104.3%	296.3	96.1%	-8.3%	0.102
32	mean, 95%CI)	249/255	(256.5–311.0)	(96.7%–112.5%)	(269.3–326.0)	(89.2%–103.6%)	(-17.3%– -1.7%)	
33	(µg/d)							
34	Iodine (median,		275.8	15.1	300.1	-30.2		
35	IQR) (µg/d)	249/255	(203.1–360.1)	(-78.3–105.3)	(218.3–391.8)	(-117.7– 90.2)		
36								
37								

* Completers refer to the participants who had 24h urine collections both at baseline and end of the trial. † Per protocol population refers to completers with complete 24h urine collections. ‡ Mean and geometric mean were adjusted for stratification variables at randomisation (school location and class size). § Adjusted for age, sex, body mass index, stratification variables at randomisation (school location and class size), and indoor and outdoor temperature.

Supplement Table 3. Iodine status assessed by 24h urinary iodine concentration using WHO's criteria, and median 24h urinary iodine concentration and 24h urinary iodine excretion for each category

Urinary iodine (µg/L)	Control						Intervention					
	Baseline			End of trial			Baseline			End of trial		
	N (%)	Iodine (median) (µg/L) (µg/24h)		N (%)	Iodine (median) (µg/L) (µg/24h)		N (%)	Iodine (median) (µg/L) (µg/24h)		N (%)	Iodine (median) (µg/L) (µg/24h)	
Children												
<100 (Iodine deficient)	10 (7.25)	85.07	94.93	10 (7.41)	84.26	114.51	5 (3.55)	86.17	89.84	11 (7.91)	86.65	113.78
100-199 (Adequate)	55 (39.86)	155.60	139.77	40 (29.63)	152.39	143.31	54 (38.30)	156.60	152.99	48 (34.53)	153.87	125.17
200-299 (Above requirement)	48 (34.78)	235.92	172.93	52 (38.52)	243.06	184.82	43 (30.50)	248.98	173.10	41 (29.5)	238.24	165.24
300 (Excessive)	25 (18.12)	430.84	249.11	33 (24.44)	371.52	279.42	39 (27.66)	357.28	236.15	39 (28.06)	411.03	260.88
ALL	138	204.60	161.70	135	222.50	176.0	141	225.30	167.00	139	217.10	154.80
Adults												
<100 (Iodine deficient)	32 (11.64)	81.31	137.25	38 (14.56)	72.84	149.13	31 (11.19)	79.49	140.35	48 (17.71)	74.71	164.03
100-199 (Adequate)	121 (44.00)	152.37	240.44	108 (41.38)	147.78	246.58	103 (37.18)	150.95	281.83	116 (42.80)	142.55	250.69
200-299 (Above requirement)	68 (24.73)	239.54	280.75	72 (27.59)	243.17	353.36	79 (28.52)	246.73	326.61	56 (20.66)	240.86	293.21
≥300 (Excessive)	54 (19.64)	372.08	420.86	43 (16.48)	351.76	460.61	64 (23.10)	372.21	423.84	51 (18.82)	364.22	535.18
ALL	275	188.80	262.10	261	183.60	281.3	277	209.4	297.40	271	176.20	258.5

Supplement Table 4. Comparison of iodine levels observed from 24h urinary iodine with that predicted from salt intake and iodine content in salt

	Control		Intervention	
	Baseline*	End of trial*	Baseline*	End of trial*
Children				
Observed from 24h urinary measurements				
Mean salt (g/d)	6.8	8.0	7.3	6.6
Median iodine (µg/d)	161.7	176.0	167.0	154.8
Iodine/salt ratio, median (µg/g)	23.8	24.4	25.0	24.9
Predicted iodine based on salt intake and iodine content in salt using the minimum level of 18 mg/kg				
Predicted iodine (µg/d)	122.4	144.0	131.4	118.8
Ratio (predicted/observed)	0.8	0.8	0.8	0.8
Adults				
Observed from 24h urinary measurements				
Mean salt (g/d)	11.3	12.1	12.6	10.4
Median iodine (µg/d)	262.1	281.3	297.4	258.5
Iodine/salt ratio, median (µg/g)	24.8	24.8	24.6	26.7
Predicted iodine based on salt intake and iodine content in salt using the minimum level of 18 mg/kg				
Predicted iodine (µg/d)	203.4	217.8	226.8	187.2
Ratio (predicted/observed)	0.8	0.8	0.8	0.7

*adjusted for stratification variables at randomisation (school location and class size).



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2-3
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	5
	2b	Specific objectives or hypotheses	5-6
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	5-6
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	Not applicable
Participants	4a	Eligibility criteria for participants	6 & Reference 13 &14
	4b	Settings and locations where the data were collected	6
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	6-7 & Reference 13 &14
	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	6
Outcomes	6b	Any changes to trial outcomes after the trial commenced, with reasons	Not applicable
	Sample size	7a	How sample size was determined
7b		When applicable, explanation of any interim analyses and stopping guidelines	Not applicable
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	Reference 13 &14
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	6
Allocation concealment	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	Reference 13 &14

1				
2	mechanism			
3				
4	Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	Reference 13 & 14
5				
6	Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	7
7				
8		11b	If relevant, description of the similarity of interventions	Not applicable
9				
10	Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	7-8
11		12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	8
12				
13	Results			
14	Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	8 & Supplement Figure
15				
16		13b	For each group, losses and exclusions after randomisation, together with reasons	8 & Supplement Figure
17				
18				
19				
20				
21	Recruitment	14a	Dates defining the periods of recruitment and follow-up	Reference 13 & 14
22				
23		14b	Why the trial ended or was stopped	Not applicable
24	Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Supplement Table 1
25				
26				
27	Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	Supplement Table 1, Table 3, & Supplement Figure
28				
29				
30				
31				
32				
33	Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	Table 1
34				
35		17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	Not applicable
36	Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	Supplement Table 2 & 3
37				
38	Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	Not applicable
39				
40				
41	Discussion			
42	Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	10-11
43				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Generalisability	21	Generalisability (external validity, applicability) of the trial findings	13
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	11-13
Other information			
Registration	23	Registration number and name of trial registry	3
Protocol	24	Where the full trial protocol can be accessed, if available	Submitted as supplement file
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	15

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

For peer review only

BMJ Open

Effect of salt reduction on iodine status assessed by 24h urinary iodine excretion in children and their families in northern China: a sub-study of a cluster randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-011168.R2
Article Type:	Research
Date Submitted by the Author:	10-Aug-2016
Complete List of Authors:	He, Feng; Queen Mary University of London, Wolfson Institute of Preventive Medicine Ma, Yuan; Peking University School of Public Health, Feng, Xiangxian; Changzhi Medical College Zhang, Wanqi; Tianjin Medical University Lin, Laixiang; Key Laboratory of Hormone and Development (Ministry of Health) Guo, Xiaohui; Tianjin Medical University Zhang, Jing; The George Institute for Global Health at Peking University Health Science Center, Niu, Wenyi; Peking University School of Public Health Wu, Yangfeng; The George Institute, MacGregor, Graham; Queen Mary University of London, Wolfson Institute of Preventive Medicine
Primary Subject Heading:	Public health
Secondary Subject Heading:	Nutrition and metabolism
Keywords:	Salt reduction, Iodine status, 24h urine collections, Cluster randomised trial

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Effect of salt reduction on iodine status assessed by 24h urinary iodine excretion in children and their families in northern China: a sub-study of a cluster randomised controlled trial

Feng J He,¹ Yuan Ma,^{1,2,3} Xiangxian Feng,⁴ Wanqi Zhang,^{5,6} Laixiang Lin,^{6,7} Xiaohui Guo,⁵ Jing Zhang,² Wenyi Niu,⁸ Yangfeng Wu,^{2,3,9} Graham A MacGregor¹

¹ Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, UK.

² The George Institute for Global Health at Peking University Health Science Center, Beijing, China.

³ Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing, China.

⁴ Changzhi Medical College, Shanxi, China.

⁵ School of Public Health, Tianjin Medical University, Tianjin, China.

⁶ Key Laboratory of Hormone and Development (Ministry of Health), China.

⁷ Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.

⁸ Department of Social Medicine and Health Education, Peking University School of Public Health, Beijing, China.

⁹ Peking University Clinical Research Institute, Beijing, China.

Running Title: Effect of salt reduction on iodine status

Correspondence to:

Dr. Feng J He

Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ.

Tel: +44 (0)20 7882 6266

Fax: +44 (0)20 7882 6270

E-mail: f.he@qmul.ac.uk

Professor Wanqi Zhang

School of Public Health, Tianjin Medical University, Tianjin, China. 300070

Tel: +86 (0)22 8333 6595

Fax: +86 (0)22 8333 6608

E-mail: wqzhang@tmu.edu.cn

Abstract

Objective To study the effect of salt reduction on iodine status and to determine whether iodine consumption was still adequate after salt reduction in a population where universal salt iodisation is mandatory.

Design A sub-study of a cluster randomised controlled trial, with schools randomly assigned to either the intervention or control group.

Setting 28 primary schools in Changzhi, northern China.

Participants 279 children in grade 5 of primary school (mean age: 10.1); 553 adults (age: 43.8).

Intervention Children were educated about the harmful effects of salt and how to reduce salt intake using the schools' usual health education lessons. Children then delivered the message to their families. The duration was one school term (≈ 3.5 months).

Main outcome measure Difference between the intervention and control group in the change of iodine intake as measured by repeat 24h urinary iodine from baseline to the end of the trial.

Results At baseline, the mean salt intake was 7.0 ± 2.5 g/d in children and 11.7 ± 4.4 g/d in adults and the median iodine intake was $165.1 \mu\text{g/d}$ (IQR: 122.6-216.7) and $280.7 \mu\text{g/d}$ (IQR: 205.1-380.9) in children and adults respectively. At the end of the study, both salt and iodine decreased in the intervention compared with control group. The mean effect on salt for intervention vs control was -1.9 g/d (95% CI: -2.6 to -1.3) in children and -2.9 g/d (95% CI: -3.7 to -2.2) in adults. The mean effect on iodine was -19.3% (95% CI: -29.4% to -7.7%) in children and -11.4% (95% CI: -20.3% to -1.5%) in adults.

Conclusions With $\approx 25\%$ reduction in salt intake, there was a significant reduction in iodine consumption in northern China where salt is iodised. Despite this, iodine intake was

1
2
3 still adequate, and well above the estimated average requirement. Our findings indicate that
4
5 reducing salt to the WHO's target—30% reduction by 2025, will not compromise iodine
6
7 status.
8

9
10 **Trial registration** ClinicalTrials.gov NCT01821144.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- 24h urinary iodine excretion is the most reliable biochemical marker for assessing iodine status.
- Our study is the first to have assessed iodine status by repeat 24h urine collections in a large number of primary school children and their adult family members in northern China where universal salt iodisation is mandatory.
- Our study, for the first time, has assessed the effect of a modest reduction in salt intake on iodine status using a well-controlled randomised trial.
- The results demonstrate that $\approx 25\%$ reduction in salt intake which is close to the WHO's target, does not compromise iodine status.
- Despite all 24h urine collections followed stringent protocol with careful supervision, there might still be under collections in some participants. However, the consistent findings from various sensitivity analyses indicate that this is unlikely to alter the primary outcome.

Introduction

Iodine deficiency disorder is a global public health problem with approximately 1.88 billion people including 241 million school-age children having insufficient intake of iodine worldwide.¹ China was one of the countries that had a serious epidemic of iodine deficiency disorders.² In 1993, the WHO (World Health Organisation) and UNICEF (United Nations Children's Fund) recommended universal salt iodization to prevent and control iodine deficiency.¹ China launched a universal salt iodisation programme in 1995.³ Since then significant progress has been made in reducing iodine deficiency disorders.^{3,4} In recent years there has been debate about the optimal levels of iodine fortification in salt, particularly as salt intake is very high in China and iodine excess could also lead to thyroid diseases.^{3,5,6}

A reduction in salt intake is one of the most cost-effective public health policies to prevent hypertension and cardiovascular disease.⁷⁻⁹ The WHO recommends a 30% reduction in salt intake by 2025 for all countries around the world with an eventual target of 5 g/d.¹⁰ As salt has been used as a vehicle for iodine fortification in many countries, it is important to monitor iodine status to ensure that iodine consumption is still adequate when salt intake is reduced.

More than 90% of iodine consumed is excreted in the urine within 24-48 hours.^{11,12} Therefore, 24h urinary iodine excretion is a good marker of recent dietary iodine intake and is the ideal biochemical indicator for assessing iodine status.¹ We measured 24h urinary iodine excretion in individuals who took part in School-EduSalt (**School-based Education Programme to Reduce Salt**),^{13,14} a cluster randomised controlled trial in Changzhi, northern China where universal salt iodisation is mandatory. The primary aim of the School-EduSalt trial was to determine whether an education programme targeted at primary school children could lower salt intake in children and their families. The study collected two consecutive 24h urines at baseline and at the end of the trial using a standardised protocol with careful

1
2
3 supervision. The results showed that the education led to a significant reduction in salt intake
4
5 by approximately 25% in both children and adults compared with the controls. In this paper,
6
7 we report a pre-specified sub-study,¹⁵ the aim of which was to assess iodine status by repeat
8
9 24h urinary iodine excretion and to study the effect of salt reduction on iodine status, and in
10
11 particular to determine whether iodine consumption was still adequate after the participants
12
13 had been on a reduced salt intake for a few months.
14

15 16 17 **Methods**

18
19 A detailed description of the methods of the School-EduSalt study has been published
20
21 elsewhere^{13 14} and the abridged methods are reported here. The study was a cluster
22
23 randomised controlled trial in 28 primary schools in urban Changzhi, Northern China. From
24
25 each school, we selected one class in Grade 5 (age ≈10 years). From each class we randomly
26
27 selected 10 children who met the inclusion criteria.¹⁴ From each child's family we also
28
29 enrolled two adults. Schools were randomly assigned to either the intervention or the control
30
31 group with stratification by the location of schools and the size of the class.
32
33 Children in the intervention group were educated about the harmful effects of salt on health
34
35 and how to reduce salt intake using the schools' usual health education lessons, i.e. one 40
36
37 min lesson every two weeks.^{13 14} The salt reduction education was delivered to the whole
38
39 class in spite of only 10 children being selected for assessment. Children were asked to
40
41 deliver the salt reduction message to the families, particularly children needed to persuade the
42
43 persons who did the cooking to reduce the amount of salt used during food preparation at
44
45 home. The duration of the intervention was one school term (≈3.5 months). Children in the
46
47 control group carried on with their usual health education lessons as in the curriculum.
48
49 The primary outcome of this sub-study was the difference between the intervention and the
50
51 control group in the change of iodine intake as measured by 24h urinary iodine excretion
52
53 from baseline to the end of the trial.
54
55
56
57
58
59
60

1
2
3 Urinary iodine was measured by the Key Laboratory of Hormone and Development (Ministry
4 of Health, China), that participated in the US Centers for Disease Control and Prevention
5 EQUIP (Ensuring the Quality of Urinary Iodine Procedures) programme.¹⁶ Ammonium
6 persulfate digestion with spectrophotometric detection of the Sandell-Kolthoff reaction was
7 used for urinary iodine measurement with quality control,¹⁷ using the samples collected
8 during the study with the storage condition of -80°C. For each batch of samples, we ran four
9 levels of certified reference material—lyophilized human urine (lot nos. GBW091081,
10 GBW09110n, GBW09111a and GBW09112a; National Reference Laboratory for iodine
11 deficiency disorder, Beijing) with mean certified iodine concentrations of 67.9 µg/L (95%CI:
12 58.9 to 76.9), 195µg/L (95%CI: 185 to 205), 558 µg/L (95%CI: 541 to 575) and 885 µg/L
13 (95%CI: 857 to 913), respectively. The biochemists who performed the urinary iodine
14 measurements were not aware which group the participant was allocated.

30 **Statistical analyses**

31
32 As urinary iodine was not normally distributed, we used median and interquartile range (IQR)
33 to summarise the iodine status. Three urine samples with iodine >5000 µg/24h were outliers
34 and excluded from the analysis. All three were from the intervention group. We used the cut-
35 off points (EAR, Estimated Average Requirement and UL, Tolerable Upper Limit) as
36 recommended by the Chinese Nutrition Society¹⁸ to define iodine intake as insufficient if
37 urinary iodine was less than EAR, i.e. <65 µg/24h in children aged ≈10 or <85 µg/24h in
38 adults; adequate if iodine was between EAR and UL, i.e. 65-300 µg/24h in children or 85-600
39 µg/24h in adults; excessive if urinary iodine was more than UL, i.e. >300 µg/24h in children
40 or >600 µg/24h in adults. For the purpose of comparison with other surveys, we also reported
41 24h urinary iodine concentration and iodine status based on urinary iodine concentration
42 according the WHO's criteria (i.e. iodine deficient <100 µg/L; adequate 100-199 µg/L, above
43 requirement 200-299 µg/L; excessive ≥300 µg/L).

Our main analysis was based on intention-to-treat using linear mixed models as reported previously.^{14 19} Logarithmic transformed iodine was used, and as such, the mean effect on iodine was presented as percentage change. The statistical model was in the form: Outcome= Group+Time+Interaction (time×group)+Stratification variables at randomisation (school location and class size)+Confounding variables (age, sex, body mass index, indoor and outdoor temperature). To examine the robustness of the conclusions of the primary analysis we carried out various sensitivity analyses as specified previously.¹⁴ The number of 24h urine samples included and excluded in each analysis was shown in Supplement Figure 1.

We used SAS (version 9.4) for the analyses. Results are reported as mean, SD and 95% CI or median and IQR where appropriate. All analyses were 2-sided and P values of <0.05 were considered statistically significant.

Results

The School-EduSalt trial enrolled 279 children and 553 adults, all of whom were included in the current report. The baseline characteristics of the participants were well balanced between the intervention and the control group (Supplement Table 1). The mean age was 10.1±0.5 years for children and 43.8±12.2 years for adults.

The result on salt has been published previously.¹⁴ We report it again in this paper explicitly for the purpose of allowing the readers to compare the salt and iodine levels. At baseline, the mean salt intake as calculated from 24h urinary sodium excretion was 7.0±2.5 g/d in children and 11.7±4.4 g/d in adults. The median iodine consumption as measured by 24h urinary iodine was 165.1 µg/d (IQR: 122.6-216.7, 95% CI: 156.9 to 172.9) and 280.7 µg/d (IQR: 205.1-380.9, 95% CI: 270.3 to 293.8) in children and adults respectively.

Table 1 shows the salt and iodine intake by group, as well as their changes during the study.

From baseline to the end of the trial, both salt and iodine intake decreased in the intervention

1
2
3 group and increased in the control group. The mean effect size on salt for intervention vs
4
5 control was -1.9 g/d (95% CI: -2.6 to -1.3, $P<0.0001$) in children and -2.9 g/d (95% CI: -3.7
6
7 to -2.2, $P<0.0001$) in adults. The mean effect size on iodine was -19.3% (95% CI: -29.4% to
8
9 -7.7%, $P=0.002$) in children and -11.4% (95% CI: -20.3% to -1.5%, $P=0.03$) in adults.

10
11 Table 2 shows iodine status according to the Chinese Nutrition Society's guidelines.¹⁸ In the
12
13 intervention group, there was an increase in the proportion of individuals with iodine intake
14
15 below EAR from baseline to the end of the trial. Despite this, there were only less than 5%
16
17 children and less than 3% adults who had iodine intake below EAR after salt intake was
18
19 reduced.

20
21 The results from sensitivity analyses are shown in Supplement Table 2. The first analysis
22
23 excluded possibly incomplete 24 urine collections. As expected, the absolute levels of salt
24
25 and iodine intake were higher compared with those when all 24h urine collections were
26
27 included. However, the primary outcome, i.e. the difference between the two groups in the
28
29 change of salt and iodine intake was very similar to that from the main analysis. The results
30
31 for completers (i.e. the participants who had 24h urine collections both at baseline and end of
32
33 the trial) and per-protocol analyses (including completers with complete 24h urine
34
35 collections) were very close to those from the corresponding analyses with all participants
36
37 included.

38
39 Supplement Table 3 shows the iodine status based on 24h urinary iodine concentration using
40
41 the WHO's criteria, as well as the median 24h urinary iodine concentration and the median
42
43 24h urinary iodine excretion for each category. In both children and adults, the median 24h
44
45 urinary iodine excretions in the group classified as iodine deficient according to the WHO's
46
47 criteria (i.e. $<100 \mu\text{g/L}$) were well above EAR across the study.

48 49 50 51 52 53 54 55 56 57 58 59 60

1
2
3 Our study produced two important findings. First, the study for the first time has measured
4 iodine intake using repeat 24h urine collections in a large number of primary school children
5 and their families in northern China. A conservative estimate showed that the median
6 baseline iodine intake was 165 $\mu\text{g}/\text{d}$ in children and 281 $\mu\text{g}/\text{d}$ in adults. These intakes are
7 adequate. According to the Chinese Nutrition Society's guideline, EAR (i.e. daily intake
8 meeting the requirement of one-half of the population) is 65 $\mu\text{g}/\text{d}$ in children aged 7-10 years
9 and 85 $\mu\text{g}/\text{d}$ in adults, and RNI (recommended nutrient intake, i.e. intake meeting the
10 requirement of 97-98% of the population) is 90 $\mu\text{g}/\text{d}$ in children aged 7-10 and 120 $\mu\text{g}/\text{d}$ in
11 adults.¹⁸ The median iodine intakes in our study were 254% and 331% of EAR, and 183%
12 and 234% of RNI for children and adults respectively. Additionally, the median iodine
13 intakes were far below the tolerable upper limit of 300 $\mu\text{g}/\text{d}$ in children and 600 $\mu\text{g}/\text{d}$ in
14 adults (Figure 1).
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29
30 Second, our study is the first to have studied the effect of salt reduction, as currently
31 recommended, on iodine status in a population where salt is universally iodised. The mean
32 effect was a reduction in salt intake of 1.9 g/d in children and 2.9 g/d in adults which led to a
33 decrease in iodine intake of 19.3% and 11.4% in children and adults respectively. These
34 mean effects represent the differences between the intervention and control group in the
35 changes in salt and iodine from baseline to the end of the trial. As shown in table 1, during
36 the study, both salt and iodine intake decreased in the intervention group and increased in the
37 control group. If applying the mean reduction in iodine level (19.3% in children and 11.4% in
38 adults) to all participants irrespective of their group allocation, the average iodine intake
39 would be 133 $\mu\text{g}/\text{d}$ in children and 249 $\mu\text{g}/\text{d}$ in adults after salt reduction. These iodine levels
40 are still adequate, and 205% and 293% of EAR and 148% and 208% of RNI for children and
41 adults respectively.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 In our study, all 24h urine collections were carefully supervised with both the start and finish
4 time recorded by trained research staff. It is certain that there was no over-collection.
5

6
7 However, it is difficult to know whether there was any under-collection. Although the
8 participants who admitted to having missed urine voids, were asked to re-do 24h urine
9 collections, it is still possible that some participants did not report missing urine collection.
10

11
12 Excluding potential incomplete 24h urine collections, as expected, led to a slightly higher salt
13 and iodine intake for both baseline and end trial, and for both the intervention and the control
14 group. It is therefore likely that our main results have under-estimated the average salt and
15 iodine intake of the study population. However, this is unlikely to alter the primary outcome,
16 i.e. the difference between the intervention and control group. Indeed, various sensitivity
17 analyses have shown consistent findings (Supplement Table 2).
18
19

20
21 In Changzhi where our study was carried out, the iodine content in salt varied from 18 to 33
22 mg/kg in 2013 (data was provided by the local salt manufacturer). Based on the iodine
23 content in salt and the 24h urinary sodium and iodine excretion, we estimated that ~80% of
24 iodine in the diet was from iodised salt. The changes in 24h urinary iodine observed in our
25 study is consistent with that predicted from the changes in salt intake (Supplement Table 4).
26
27 Therefore any potential influence from other dietary sources would be small.
28

29
30 Despite 24h urinary iodine is the most reliable biochemical marker for assessing iodine
31 status, almost all previous surveys on iodine have used spot urine due to the apparent logistic
32 challenges and costs in collecting 24h urine. The WHO also endorsed the use of spot urine
33 and provided cut-offs of median spot urinary iodine concentration to categorise population's
34 iodine status.¹ However, this has been inappropriately used by previous surveys to define the
35 number of individuals who were iodine deficient.²⁰ Our study demonstrates that, in the group
36 of individuals classified as iodine deficient according to the WHO's criteria based on urinary
37 iodine concentration, the median 24h urinary iodine levels were well above EAR. These
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 findings clearly illustrate the inappropriateness of spot urine in monitoring iodine status and,
4
5 as a result, previous surveys would have over-estimated the prevalence of iodine deficiency.
6
7 It is worth noting that our study did not collect spot urine, however, 24h urinary iodine
8
9 concentration is a better index than any of the spot urine iodine concentration (e.g. casual,
10
11 first morning void). Additionally, our study shows that it is entirely feasible to collect 24h
12
13 urine not only in adults but also in primary school children. The WHO has recommended 24h
14
15 urine collections for determining and monitoring population salt intake.²¹ It will be more
16
17 efficient and highly cost-effective if the iodine intake is monitored in the same population
18
19 surveys using the same methods.
20
21

22
23 In China, since the introduction of universal salt iodisation in 1995, regular surveys using
24
25 casual spot urine have been carried out to monitor the population's iodine status and adjust
26
27 the iodine content in salt accordingly.³ The surveys were largely conducted in primary
28
29 schoolchildren aged 8-10 because these children are readily accessible in schools and they
30
31 have been assumed to have iodine intakes characteristic of general populations. At country
32
33 level, the median spot urinary iodine in schoolchildren aged 8-10 increased from 165 µg/L in
34
35 1995 to over 300 µg/L by 1999 and declined to 241 µg/L and 246 µg/L in 2002 and 2005,
36
37 respectively.³ This was in parallel with the changes of iodine content in salt which increased
38
39 from 16.2 mg/kg in 1995, to 42.3 mg/kg in 1999, then declined to 30.8 mg/kg in 2005 and
40
41 has remained at this level.³ These changes reflect the alterations of the standard for
42
43 'qualified' iodised salt set by the Chinese Ministry of Health.³ Initially the regulation for
44
45 iodine content was ≥ 20 mg/kg in 1995. As there was no upper limit, most salt producers
46
47 tended to iodise salt with iodine over 40 mg/kg. In 1997, an upper limit of 60 mg/kg was set.
48
49 National iodine survey at the time indicated an excessive population iodine intake and such
50
51 data led to a reduction in the upper limit from 60 to 50 mg/kg in 2002. The standard of 35 ± 15
52
53 (or 20-50) mg/kg had remained till 2012 when provinces were allowed to choose from the
54
55
56
57
58
59
60

1
2
3 three standards, i.e. 20 (14-26), 25 (18-33) and 30 (21-39) mg/kg, depending on local diet and
4
5 spot urinary iodine concentration.²²
6

7
8 In our study site—Changzhi, the changes in urinary iodine followed a similar pattern to that
9
10 occurred nationally although some of the surveys showed a higher iodine level. The most
11
12 recent survey in Changzhi was carried out in 2010 and showed that the median spot urinary
13
14 iodine was 241, 284 and 310 µg/L in schoolchildren aged 8, 9 and 10 respectively.²³ In our
15
16 study which was done in 2013, the median baseline 24h urinary iodine concentration was
17
18 215.8 µg/L for schoolchildren aged ≈10 years. The lower iodine level observed in our study
19
20 could be largely due to the decrease in iodine content in salt following the change in the
21
22 standard for iodised salt (i.e. from 20-50 mg/kg to 18-33 mg/kg) in 2012.
23

24
25 Despite our study was carried out in Changzhi and included individuals who mainly ate
26
27 home-made meals, the results could be broadly applicable to most parts of China for the
28
29 following reasons: (1) Universal salt iodisation is mandatory in China, and the food
30
31 manufacturers and restaurants also use iodised salt; (2) The iodine content in salt (18-33
32
33 mg/kg) in Changzhi is similar to the national level (14-39 mg/kg)²²; (3) Salt is the major
34
35 source of iodine in the diet across China. Although there is a variation in iodine level from
36
37 natural sources such as water and foods, iodised salt contributes to 60-80% of total iodine
38
39 intake in most parts of China.^{24 25} In Changzhi where our study was carried out, iodised salt
40
41 accounts for ≈80% of iodine intake (i.e. at the higher end of the range in China). The iodine
42
43 intake in our study population was still adequate after an approximate 25% reduction in salt
44
45 intake for 3.5 months, it is therefore most likely that the same reduction in salt if achieved
46
47 across China would not compromise iodine status. The findings of our study, however, may
48
49 not be generalisable to populations in other countries due to a number of features in the
50
51 setting, such as universal salt iodisation and high contribution of discretionary salt to total salt
52
53 intake in the Chinese diet.
54
55
56
57
58
59
60

Conclusions

Our study demonstrates that in northern China where universal salt iodisation is mandatory, a reduction in salt intake by $\approx 25\%$ which is close to the WHO's target of 30% reduction by 2025 does not compromise iodine status as measured by repeat 24h urinary iodine excretion in both children and adults. These findings provide strong support for the WHO's recommendations to reduce population salt intake to prevent hypertension and cardiovascular disease, and to improve iodine intake by fortifying salt with iodine to prevent iodine deficiency.

Currently many countries have started salt reduction initiatives and also implemented salt iodisation programmes.²⁶ However, there is a lack of coordination between the two. To maximise the benefits, there is an urgent need for close coordination and collaboration, particularly in disseminating consistent messages and monitoring population salt and iodine intake using the same methods which will provide valuable data required for appropriate adjustment of the iodine level in salt after population salt intake is reduced. This will be the most cost-effective way in implementing the two important public health policies.

Acknowledgements

We thank Peter Sever, Francesco Cappuccio, Kiang Liu, and Dong Zhao for their support and advice; the Changzhi Education Bureau, the headteachers and teachers of all participating schools, and children and their families who were involved in the research; all members of the field research team, particularly Jianhui Yuan, Yanbo Han, Peifen Duan, Zhifang Li, Jianbing Zhang, Cailing Wei, Yanli Zhai, Ruikai Zhu, Hui Yang, and Xiaoyun Wang; Jun Ma, Haijun Wang, Yide Yang, and Xiaorui Shang for their contribution and help with the development of the education materials; Yina Sun, Yan Ye, and Yongmei Li for their contribution to the measurement of urinary iodine.

Trial Steering Committee: Peter Sever (chair), Francesco Cappuccio, Kiang Liu, Dong Zhao, Feng He, Yangfeng Wu, and Graham MacGregor.

Contributors: FJH, YW and GAM designed the School-EduSalt trial. WZ developed the protocol for urinary iodine measurement and interpreted the iodine results. WZ, LL and XG organised urinary iodine measurement. JZ and YM performed quality control for iodine measurement. XF, JZ and YM contributed to data collection. FJH and YM developed the analysis plan, performed statistical analyses and took responsibility for the integrity of the data and the accuracy of the data analysis. FH wrote the manuscript. All authors contributed to the revision and approved the final manuscript. FJH is guarantor.

Funding: The School-EduSalt trial was funded by the UK Medical Research Council (MR/J015903/1) and it was part of the GACD (Global Alliance for Chronic Disease) Hypertension Programme. The measurement of iodine was funded by National Natural Science Foundation of China (81330064, 81273057). The funder of the study had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the article for publication.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare no financial relationships with any organisations that might have an interest in the submitted work in the previous three years. FJH is a member of Consensus Action on Salt & Health (CASH) and World Action on Salt & Health (WASH). Both CASH and WASH are non-profit charitable organisations and FJH does not receive any financial support from CASH or WASH. GAM is Chairman of Blood Pressure UK (BPUK), Chairman of CASH, WASH and Action on Sugar (AoS). BPUK, CASH, WASH and AoS are non-profit charitable organisations. GAM does not receive any financial support from any of these organisations. YM was sponsored by the China Scholarship Council while she was carrying out statistical analysis for this study at the Wolfson Institute of Preventive Medicine, Queen Mary University of London. Other authors declare that they have no conflicts of interest.

Ethical approval: The study protocol was approved by Queen Mary (University of London) Research Ethics Committee (QMREC2012/81) and Peking University Health Science Centre IRB (IRB00001052-12072). Permissions were obtained from the local education authority (i.e. Changzhi Education Bureau) and head-teachers of the schools. All participants who took part in the assessments gave written informed consent. For children, participant assent and parental written consent were obtained.

Data sharing: No additional data available.

REFERENCES

1. WHO 2014. Fortification of food-grade salt with iodine for the prevention and control of iodine deficiency disorders. Guideline http://www.who.int/nutrition/publications/guidelines/fortification_foodgrade_saltwithiodine/en/ (Accessed 27 January 2015).
2. Ma T, Guo J, Wang F. The epidemiology of iodine-deficiency diseases in China. *Am J Clin Nutr* 1993;57:264S-66S.
3. Li S, Zheng Q, Xu J, Gorstein J, Wang H, Dong H. Iodine excess or not: analysis on the necessity of reducing the iodine content in edible salt based on the national monitoring results. *Asia Pac J Clin Nutr* 2011;20:501-6.
4. Pearce EN, Andersson M, Zimmermann MB. Global iodine nutrition: Where do we stand in 2013? *Thyroid* 2013;23:523-8.
5. Teng W, Shan Z, Teng X, Guan H, Li Y, Teng D, et al. Effect of iodine intake on thyroid diseases in China. *N Engl J Med* 2006;354:2783-93.
6. Sang Z, Wang PP, Yao Z, Shen J, Halfyard B, Tan L, et al. Exploration of the safe upper level of iodine intake in euthyroid Chinese adults: a randomized double-blind trial. *Am J Clin Nutr* 2012;95:367-73.
7. He FJ, MacGregor GA. Reducing population salt intake worldwide: from evidence to implementation. *Prog Cardiovasc Dis* 2010;52:363-82.
8. Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. *Lancet* 2007;370:2044-53.
9. National Institute for Health and Clinical Excellence (NICE). Guidance on the prevention of cardiovascular disease at the population level. <http://guidance.nice.org.uk/PH25>
10. WHO issues new guidance on dietary salt and potassium, 31 January 2013. http://www.who.int/mediacentre/news/notes/2013/salt_potassium_20130131/en/
11. Nath SK, Moinier B, Thuillier F, Rongier M, Desjeux JF. Urinary excretion of iodide and fluoride from supplemented food grade salt. *Int J Vitam Nutr Res* 1992;62:66-72.
12. Jahreis G, Hausmann W, Kiessling G, Franke K, Leiterer M. Bioavailability of iodine from normal diets rich in dairy products--results of balance studies in women. *Exp Clin Endocrinol Diabetes* 2001;109:163-7.
13. He FJ, Wu Y, Ma J, Feng X, Wang H, Zhang J, et al. A school-based education programme to reduce salt intake in children and their families (School-EduSalt): protocol of a cluster randomised controlled trial. *BMJ Open* 2013;3:pii: e003388.
14. He FJ, Wu Y, Feng XX, Ma J, Ma Y, Wang H, et al. School based education programme to reduce salt intake in children and their families (School-EduSalt): cluster randomised controlled trial. *BMJ* 2015;350:h770.
15. He FJ, Ma Y, Feng X, Zhang W, Lin L, Guo X, et al. Effect of salt reduction on iodine status in children and their families in northern China: a sub-study of a cluster-randomised controlled trial. *Lancet* 2015;386:34.
16. Centres for Disease Control and Prevention (CDC). The Challenge of Iodine Deficiency Disorder. A Decade of CDC's Ensuring the Quality of Urinary Iodine Procedures Program www.cdc.gov/labstandards/pdf/equip/EQUIP_Booklet.pdf (Accessed 30 January 2015).

- 1
2
3 17. Zhang Y, Yan Y, Liu L, Sun Y, Li W, Hua J, et al. Revised method with low usage
4 amount of arsenic trioxide for testing urinary iodine by As (III)-Ce⁴⁺ catalytic
5 spectrophotometry using ammonium persulfate digestion. *Chin J Endemiol* 2013;32:95-
6 100.
7
8 18. Chinese Nutrition Society, Chinese dietary reference intakes 2013, Science Press,
9 2014, Beijing, ISBN 978-7-03-041401-4.
10
11 19. Carpenter JR, Kenward MG. Missing data in randomised controlled trials-a practical
12 guide. London School of Hygiene.
13 2007:[https://www.researchgate.net/publication/228754654_Missing_Data_in_Randomise](https://www.researchgate.net/publication/228754654_Missing_Data_in_Randomised_Controlled_Trials-A_Practical_Guide)
14 [d_Controlled_Trials-A_Practical_Guide](https://www.researchgate.net/publication/228754654_Missing_Data_in_Randomised_Controlled_Trials-A_Practical_Guide) (Accessed 14 June 2016).
15
16 20. Zimmermann MB, Andersson M. Assessment of iodine nutrition in populations: past,
17 present, and future. *Nutr Rev* 2012;70:553-70.
18
19 21. WHO/PAHO Regional Expert Group for Cardiovascular Disease Prevention through
20 Population-wide Dietary Salt Reduction. Protocol for population level of sodium
21 determination in 24-hour urine samples
22 [http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=21488&I](http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=21488&Itemid)
23 [temid](http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=21488&Itemid) (accessed 21 July 2015).
24
25 22. People's Republic of China National Standard. National food safety standards - Iodine
26 content in salt. GB 26878—2011. [http://www.shfda.gov.cn/spaqbz/GB26878-](http://www.shfda.gov.cn/spaqbz/GB26878-2011%20%E9%A3%9F%E7%94%A8%E7%9B%90%E7%A2%98%E5%90%AB%E9%87%8F.pdf)
27 [2011%20%E9%A3%9F%E7%94%A8%E7%9B%90%E7%A2%98%E5%90%AB%E9%](http://www.shfda.gov.cn/spaqbz/GB26878-2011%20%E9%A3%9F%E7%94%A8%E7%9B%90%E7%A2%98%E5%90%AB%E9%87%8F.pdf)
28 [87%8F.pdf](http://www.shfda.gov.cn/spaqbz/GB26878-2011%20%E9%A3%9F%E7%94%A8%E7%9B%90%E7%A2%98%E5%90%AB%E9%87%8F.pdf) (Accessed on 9 April 2015).
29
30 23. Guo WP, Chen CS, Duan HY. Analysis of urinary iodine result of 1208 children in
31 Changzhi. *Chinese Journal of Health Laboratory Technology* 2010;5:1173-74.
32
33 24. Wu Y, Li X, Chang S, Liu L, Zou S, Hipgrave DB. Variable iodine intake persists in the
34 context of universal salt iodization in China. *J Nutr* 2012;142:1728-34.
35
36 25. Song X, Li F, Liu Z, He Y, Sui H, Mao W, et al. Assessment of dietary iodine intake of
37 population in non-high-iodine areas in China. *Journal of Hygien Research* 2011;40:138-
38 41.
39
40 26. Campbell NR, Dary O, Cappuccio FP, Neufeld LM, Harding KB, Zimmermann MB.
41 Need for coordinated programs to improve global health by optimizing salt and iodine
42 intake. *Rev Panam Salud Publica* 2012;32:281-6.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Legend to figures.**
4

5 **Figure 1.** Mean salt, median iodine intake and their 95% confidence intervals in children (A)
6
7 and adults (B). EAR: Estimated average requirement; RNI: Recommended nutrient intake;
8
9
10 UL: Tolerable upper limit.

11 **Supplement Figure 1.** Trial profile. ITT: Intention-to-treat.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Table 1. Salt and iodine intake as calculated from 24h urinary sodium and iodine excretion based on intention-to-treat analysis

Outcome	Control			Intervention			Mean effect† (intervention vs control)	P value
	Baseline*	End of trial*	Change from baseline*	Baseline*	End of trial*	Change from baseline*		
Children								
Salt, mean‡ (95%CI) (g/d)	6.8 (6.2–7.4)	8.0 (7.4–8.6)	1.2 (0.7–1.7)	7.3 (6.7–7.9)	6.6 (6.0–7.2)	-0.7 (-1.2– -0.2)	-1.9 (-2.6– -1.3)	<0.0001
Iodine								
Geometric mean (95%CI) (µg/d)	162.8 (146.7–180.5)	187.5 (168.9–208.0)	115.2% (104.7%–126.7%)	173.7 (156.7–192.4)	163.2 (147.2–180.9)	94.0% (85.6%–103.2%)	-19.3% (-29.4%– -7.7%)	0.002
Median (IQR) (µg/d)	161.7 (117.7–209.5)	176.0 (136.5–237.2)	27.4 (-18.3–76.7)	167.0 (128.9–217.7)	154.8 (118.6–234.1)	-13.1 (-54.5–37.8)		
Adults								
Salt, mean (95%CI) (g/d)	11.3 (10.5–12.1)	12.1 (11.3–12.9)	0.8 (0.2–1.3)	12.6 (11.8–13.3)	10.4 (9.7–11.2)	-2.1 (-2.7– -1.6)	-2.9 (-3.7– -2.2)	<0.0001
Iodine								
Geometric mean (95%CI) (µg/d)	271.2 (245.1–300.1)	284.6 (256.9–315.2)	104.9% (97.2%–113.3%)	291.2 (263.3–322.1)	271.9 (245.7–301.0)	93.4% (86.6%–100.7%)	-11.4% (-20.3%– -1.5%)	0.030
Median (IQR) (µg/d)	262.1 (197.8–357.5)	281.3 (207.9–387.6)	10.7 (-72.8–105.3)	297.4 (213.2–390.8)	258.5 (199.8–350.0)	-36.5 (-128.4–88.9)		

* Mean and geometric mean were adjusted for stratification variables at randomisation (school location and class size). †Adjusted for age, sex, body mass index, stratification variables at randomisation (school location and class size), and indoor and outdoor temperature. ‡The results for salt were taken from previous report.¹⁴

Table 2. Iodine status assessed by 24h urinary iodine excretion

Category	Control		Intervention	
	Baseline	End of trial	Baseline	End of trial
	N (%)	N (%)	N (%)	N (%)
Children				
<65 (µg/d) (Estimated average requirement)	5 (3.62)	1 (0.74)	1 (0.71)	6 (4.32)
65-300 (µg/d)	123 (89.13)	114 (84.44)	128 (90.78)	119 (85.61)
>300 (µg/d) (Tolerable upper limit)	10 (7.25)	20 (14.81)	12 (8.51)	14 (10.07)
Adults				
<85 (µg/d) (Estimated average requirement)	3 (1.09)	4 (1.53)	2 (0.72)	7 (2.58)
85-600 (µg/d)	260 (94.55)	243 (93.10)	263 (94.95)	243 (89.67)
>600 (µg/d) (Tolerable upper limit)	12 (4.36)	14 (5.36)	12 (4.33)	21 (7.75)



Mean salt, median iodine intake and their 95% confidence intervals in children (A) and adults (B). EAR: Estimated average requirement; RNI: Recommended nutrient intake; UL: Tolerable upper limit.

93x57mm (300 x 300 DPI)

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ONLINE SUPPLEMENT

Effect of salt reduction on iodine status assessed by 24h urinary iodine excretion in children and their families in northern China: a sub-study of a cluster randomised controlled trial

Feng J He,¹ Yuan Ma,^{1,2,3} Xiangxian Feng,⁴ Wanqi Zhang,^{5,6} Laixiang Lin,^{6,7} Xiaohui Guo,⁵ Jing Zhang,² Wenyi Niu,⁸ Yangfeng Wu,^{2,3,9}
Graham A MacGregor¹

¹ Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, UK.

² The George Institute for Global Health at Peking University Health Science Center, Beijing, China.

³ Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing, China.

⁴ Changzhi Medical College, Shanxi, China.

⁵ School of Public Health, Tianjin Medical University, Tianjin, China.

⁶ Key Laboratory of Hormone and Development (Ministry of Health), China.

⁷ Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.

⁸ Department of Social Medicine and Health Education, Peking University School of Public Health, Beijing, China.

⁹ Peking University Clinical Research Institute, Beijing, China.

Correspondence to:

Dr. Feng J He

Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine & Dentistry, Queen Mary University of London,
Charterhouse Square, London EC1M 6BQ.

Tel: +44 (0)20 7882 6266

Fax: +44 (0)20 7882 6270

E-mail: f.he@qmul.ac.uk

Professor Wanqi Zhang

School of Public Health, Tianjin Medical University, Tianjin, China. 300070

Tel: +86 (0)22 8333 6595

Fax: +86 (0)22 8333 6608

E-mail: wqzhang@tmu.edu.cn

Supplement Table 1. Baseline characteristics of the participants*

Parameters	Control	Intervention	All
Children			
Number of schools	14	14	28
Number of children	138	141	279
Boys, N (%)	67 (48.6)	67 (47.5)	134 (48.0)
Age (year)	10.2 (0.5)	10.0 (0.5)	10.1 (0.5)
Weight (kg)	33.3 (7.2)	33.4 (7.8)	33.3 (7.5)
Height (cm)	140.7 (6.6)	139.2 (6.2)	140.0 (6.5)
Body mass index (kg/m ²)	16.7 (2.7)	17.1 (3.2)	16.9 (3.0)
Adults			
Number of adults	275	278	553
Men, N (%)	133 (48.4)	135 (48.6)	268 (48.5)
Parents, N (%)	208 (75.6)	203 (73.0)	411 (74.3)
Grandparents, N (%)	67 (24.4)	75 (27.0)	142 (25.7)
Age (year)	43.6 (11.8)	43.9 (12.5)	43.8 (12.2)
Weight (kg)	66.2 (12.9)	66.1 (11.6)	66.2 (12.3)
Height (cm)	162.8 (8.7)	162.4 (8.0)	162.6 (8.4)
Body mass index (kg/m ²)	24.9 (3.6)	25.0 (3.4)	24.9 (3.5)

*Data are means (SD) unless otherwise specified.

Supplement Table 2. Sensitivity analysis for salt and iodine intake as calculated from 24h urinary sodium and iodine excretion

Outcome	Number of participant Control /Intervention	Control		Intervention		Adjusted difference (intervention vs control)	P value
		Baseline [‡]	Change from baseline [‡]	Baseline [‡]	Change from baseline [‡]		
Population excluding possibly incomplete 24h urine							
Children							
Salt (mean, 95%CI) (g/d)	138/140	7.0 (6.4–7.6)	1.2 (0.7–1.6)	7.5 (6.9–8.1)	-0.7 (-1.1 – -0.2)	-1.9 (-2.6– -1.2)	<0.0001
Iodine (geometric mean, 95%CI) (µg/d)	138/140	170.8 (155.0–188.2)	112.9% (102.7%–124.2%)	180.0 (163.6–198.1)	95.4% (86.9%–104.8%)	-16.5% (-26.9%– -4.6%)	0.008
Iodine (median, IQR) (µg/d)	138/140	166.5 (119.0–220.4)	27.3 (-20.6–79.0)	175.4 (131.3–228.7)	-9.3 (-52.4–39.0)		
Adults							
Salt (mean, 95%CI) (g/d)	273/275	11.6 (10.8–12.3)	0.8 (0.3–1.4)	12.8 (12.1–13.6)	-2.1 (-2.6–-1.6)	-3.0 (-3.7– -2.2)	<0.0001
Iodine (geometric mean, 95%CI) (µg/d)	273/275	280.7 (255.0–308.9)	104.6% (97.1%–112.7%)	298.0 (270.9–327.7)	95.6% (88.8%–102.9%)	-9.5% (-18.3%–0.2%)	0.055
Iodine (median, IQR) (µg/d)	273/275	275.7 (201.9–360.1)	15.1 (-78.3–105.3)	300.5 (219.2–392.5)	-30.2 (-117.7–90.2)		
Completers*							
Children							
Salt (mean, 95%CI) (g/d)	135/139	6.8 (6.2–7.4)	1.2 (0.8–1.7)	7.2 (6.6–7.9)	-0.7 (-1.2– -0.2)	-1.9 (-2.6– -1.3)	<0.0001
Iodine (geometric mean, 95%CI) (µg/d)	135/139	162.0 (146.0–180.0)	115.4% (104.9%–126.9%)	173.5 (156.4–192.4)	94.0% (85.6%–103.2%)	-19.3% (-29.4%– -7.8%)	0.002

1	Iodine (median,		160.9	27.4	169.6	-13.1		
2	IQR) (µg/d)	135/139	(117.7–208.1)	(-18.3–76.7)	(128.5–221.6)	(-54.5–37.8)		
3								
4								
5								
6	Adults							
7	Salt (mean,		11.4	0.8	12.7	-2.2	-3.0	<0.0001
8	95%CI) (g/d)	261/271	(10.6–12.1)	(0.2–1.3)	(11.9–13.5)	(-2.7– -1.6)	(-3.7– -2.2)	
9	Iodine (geometric		272.1	104.7%	292.6	93.1%	-11.1%	0.030
10	mean, 95%CI)	261/270	(245.3–301.7)	(96.9%–113.1%)	(264.1–324.3)	(86.3%–100.4%)	(-20.1%– -1.1%)	
11	(µg/d)							
12	Iodine (median,		261.8	10.7	297.7	-36.5		
13	IQR) (µg/d)	261/270	(197.8–348.8)	(-72.8–105.3)	(213.2–391.8)	(-128.4– 88.9)		
14								
15								
16	Per protocol population†							
17								
18	Children							
19	Salt (mean,		7.0	1.2	7.5	-0.7	-1.9	<0.0001
20	95%CI) (g/d)	132/137	(6.4–7.6)	(0.7–1.7)	(6.9–8.1)	(-1.1– -0.2)	(-2.6– -1.3)	
21	Iodine (geometric		169.5	114.1%	179.6	95.9%	-16.8%	0.007
22	mean, 95%CI)	132/137	(154.1–186.4)	(103.7%–125.5%)	(163.5–197.2)	(87.3%–105.3%)	(-27.2%– -4.9%)	
23	(µg/d)							
24	Iodine (median,		166.5	27.3	178.8	-9.3		
25	IQR) (µg/d)	132/137	(120.3–216.8)	(-20.6–79.0)	(131.3–228.7)	(-52.4–39.0)		
26								
27								
28	Adults							
29	Salt (mean,		11.6	0.9	12.9	-2.1	-3.0	<0.0001
30	95%CI) (g/d)	249/256	(10.8–12.3)	(0.3–1.4)	(12.2–13.7)	(-2.6– -1.6)	(-3.7– -2.3)	
31	Iodine (geometric		282.4	104.3%	296.3	96.1%	-8.3%	0.102
32	mean, 95%CI)	249/255	(256.5–311.0)	(96.7%–112.5%)	(269.3–326.0)	(89.2%–103.6%)	(-17.3%–1.7%)	
33	(µg/d)							
34	Iodine (median,		275.8	15.1	300.1	-30.2		
35	IQR) (µg/d)	249/255	(203.1–360.1)	(-78.3–105.3)	(218.3–391.8)	(-117.7– 90.2)		
36								
37								
38								

* Completers refer to the participants who had 24h urine collections both at baseline and end of the trial. † Per protocol population refers to completers with complete 24h urine collections. ‡ Mean and geometric mean were adjusted for stratification variables at randomisation (school location and class size). § Adjusted for age, sex, body mass index, stratification variables at randomisation (school location and class size), and indoor and outdoor temperature.


Supplement Table 3. Iodine status assessed by 24h urinary iodine concentration using WHO's criteria, and median 24h urinary iodine concentration and 24h urinary iodine excretion for each category

Urinary iodine (µg/L)	Control					Intervention						
	Baseline		End of trial			Baseline		End of trial				
	N (%)	Iodine (median) (µg/L) (µg/24h)		N (%)	Iodine (median) (µg/L) (µg/24h)		N (%)	Iodine (median) (µg/L) (µg/24h)		N (%)	Iodine (median) (µg/L) (µg/24h)	
Children												
<100 (Iodine deficient)	10 (7.25)	85.07	94.93	10 (7.41)	84.26	114.51	5 (3.55)	86.17	89.84	11 (7.91)	86.65	113.78
100-199 (Adequate)	55 (39.86)	155.60	139.77	40 (29.63)	152.39	143.31	54 (38.30)	156.60	152.99	48 (34.53)	153.87	125.17
200-299 (Above requirement)	48 (34.78)	235.92	172.93	52 (38.52)	243.06	184.82	43 (30.50)	248.98	173.10	41 (29.5)	238.24	165.24
300 (Excessive)	25 (18.12)	430.84	249.11	33 (24.44)	371.52	279.42	39 (27.66)	357.28	236.15	39 (28.06)	411.03	260.88
ALL	138	204.60	161.70	135	222.50	176.0	141	225.30	167.00	139	217.10	154.80
Adults												
<100 (Iodine deficient)	32 (11.64)	81.31	137.25	38 (14.56)	72.84	149.13	31 (11.19)	79.49	140.35	48 (17.71)	74.71	164.03
100-199 (Adequate)	121 (44.00)	152.37	240.44	108 (41.38)	147.78	246.58	103 (37.18)	150.95	281.83	116 (42.80)	142.55	250.69
200-299 (Above requirement)	68 (24.73)	239.54	280.75	72 (27.59)	243.17	353.36	79 (28.52)	246.73	326.61	56 (20.66)	240.86	293.21
≥300 (Excessive)	54 (19.64)	372.08	420.86	43 (16.48)	351.76	460.61	64 (23.10)	372.21	423.84	51 (18.82)	364.22	535.18
ALL	275	188.80	262.10	261	183.60	281.3	277	209.4	297.40	271	176.20	258.5

Supplement Table 4. Comparison of iodine levels observed from 24h urinary iodine with that predicted from salt intake and iodine content in salt

	Control		Intervention	
	Baseline	End of trial	Baseline	End of trial
Children				
Observed from 24h urinary measurements				
Mean salt (g/d)*	6.8	8.0	7.3	6.6
Median iodine (µg/d)	161.7	176.0	167.0	154.8
Iodine/salt ratio, median (µg/g)	23.8	24.4	25.0	24.9
Predicted iodine based on salt intake and iodine content in salt using the minimum level of 18 mg/kg				
Predicted iodine (µg/d)	122.4	144.0	131.4	118.8
Ratio (predicted/observed)	0.8	0.8	0.8	0.8
Adults				
Observed from 24h urinary measurements				
Mean salt (g/d)*	11.3	12.1	12.6	10.4
Median iodine (µg/d)	262.1	281.3	297.4	258.5
Iodine/salt ratio, median (µg/g)	24.8	24.8	24.6	26.7
Predicted iodine based on salt intake and iodine content in salt using the minimum level of 18 mg/kg				
Predicted iodine (µg/d)	203.4	217.8	226.8	187.2
Ratio (predicted/observed)	0.8	0.8	0.8	0.7

*adjusted for stratification variables at randomisation (school location and class size).



Trial profile

233x307mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2-3
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	5
	2b	Specific objectives or hypotheses	5-6
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	5-6
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	Not applicable
Participants	4a	Eligibility criteria for participants	6 & Reference 13 &14
	4b	Settings and locations where the data were collected	6
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	6-7 & Reference 13 &14
	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	6
Outcomes	6b	Any changes to trial outcomes after the trial commenced, with reasons	Not applicable
	Sample size	7a	How sample size was determined
7b		When applicable, explanation of any interim analyses and stopping guidelines	Not applicable
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	Reference 13 &14
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	6
Allocation concealment	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	Reference 13 &14

1				
2	mechanism			
3				
4	Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	Reference 13 & 14
5				
6	Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	7
7				
8		11b	If relevant, description of the similarity of interventions	Not applicable
9				
10	Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	7-8
11		12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	8
12				
13	Results			
14	Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	8 & Supplement Figure
15				
16		13b	For each group, losses and exclusions after randomisation, together with reasons	8 & Supplement Figure
17				
18				
19				
20				
21	Recruitment	14a	Dates defining the periods of recruitment and follow-up	Reference 13 & 14
22				
23		14b	Why the trial ended or was stopped	Not applicable
24	Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Supplement Table 1
25				
26				
27	Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	Supplement Table 1, Table 3, & Supplement Figure
28				
29				
30				
31				
32				
33	Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	Table 1
34				
35		17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	Not applicable
36	Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	Supplement Table 2 & 3
37				
38	Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	Not applicable
39				
40				
41	Discussion			
42	Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	10-11
43				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Generalisability	21	Generalisability (external validity, applicability) of the trial findings	13
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	11-13
Other information			
Registration	23	Registration number and name of trial registry	3
Protocol	24	Where the full trial protocol can be accessed, if available	Submitted as supplement file
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	15

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.